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Abstract of the Dissertation 
 
Multiplex Drug Screenings to Discover Host Oriented 
Therapies Against Infectious Diseases 
By William Leonardi 
Keck Graduate Institute of Applied Life Sciences: 2016 
 
Drug resistance is a longstanding and still-increasing threat to the effective 
treatment of infectious diseases. Discovering drugs that target host proteins 
involved in pathogenicity is a strategy that could address this problem. 
Unfortunately, there are currently no FDA-approved infectious disease therapies 
that specifically target host proteins. Our goal is to develop a method to i) quickly 
discover new drugs for the treatment infectious diseases, ii) identify the specific 
host protein target of the drugs, iii) investigate the broad spectrum application of 
the drugs. To find these types of drugs, we employed a novel multiplex drug 
screening method in which we used disease pathway knowledge to more 
effectively screen a library of FDA-approved drugs. We utilized a cell-based 
survival assay to determine safety and efficacy and a biochemical-based assay 
to determine the host protein target of the drugs. This methodology led to the 
discovery of two approved drugs and their host protein targets. In addition, these 
drugs were shown to be safe and effective in animal models. These results 
suggest that our novel multiplex drug screening method can be used to address 
the drug resistance problem.
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Chapter 1 – Research Background 
Major Probem with Current Infectious Disease Therapies 
Despite the advancement of science and disease treatment, infectious diseases 
are still the leading cause of mortality in millenial century1. Between 1980 and 
2013 there were 12,102 outbreaks of 215 human infectious diseases2. Infectious 
diseases contribute to 44 million disease cases a year, occuring in 219 nations2. 
Various efforts have been deployed to manage the outbreak of infectious 
diseases, the primary methof being prescribing antimicrobial therapies. 
Unfortunately, the effort of combating infectious diseases by prescribing 
antimicrobial thereapy also contributed to a three fold increas in infectious 
disease outbreaks between 1980 and 2010 (Figure 1)2. The emergence and re-
emergence of infectious diseases and increasing cases of anti-microbial 
resistance  press the need to discover effective therapies against them. 
 
Figure 1: Total number of outbreaks steadily increased between 1980 and 
2010, disease outbreak predominantly caused by bacteria2 
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Anti-microbials as Frontline Therapeutics for Infectious 
Diseases 
The definition of antimicrobials are outlined by American Chemistry Society 
(ACS), as compounds that are produced by bacteria or fungi which have the 
ability to inhibit or kill the competing microbial species3. Penicillin was the first 
effective and successful antimicrobial therapy that was used for various of 
infections such as pneunomia and gonorrhea3. Penicillin was first discovered by 
Alexander Flemming in 1928 when he discovered a halo on one of his petri 
dishes that contained Staphylococus bacteria. Through this observation, he 
concluded that the halo was caused by the Penicillium fungus or mold4. The 
discovery of penicillin was further studied by a group of scientists from Oxford 
University who produced it for use in humans in 19413. Later on, multiple 
pharmaceutical companies developed efforts to scale up the production process. 
By late 1943 the mass production of penicillin began and was effectively used to 
fight infections during World War II3. By the end of the 1940s, Penicillin was 
widely available for humans at an affordable cost. The discovery of penicillin has 
served as the foundation for the extensive research of discovering various 
antimicrobial therapies for many years to come.  
 
The Development of Antimicrobial Resistance 
The success of Penicilin served as a foundation for a new era of antimicrobial 
therapy. Between 1940 and 1960, there was extensive discovery of a new class 
of anti microbials to fight infections5. Understanding the significance and clinical 
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benefit of antimicrobials as a therapy, people started to misuse and overuse the 
then, which are the two main contributing factors that lead to antimicrobial 
resistance6. Due to this fact, antimicrobial resistance developed not long after 
antimicrobials became widely used (Figure 2). Pathogens started to develop 
resistance against antimicrobials within a short amount of time and the problems 
of anti-microbial resistance will remain an issue for many years to come.  
   
Figure 2: Timeline of antimicrobial first use and development of 
antimicrobial resistance5 
 
The hypothesis underlying the development of antimicrobial resistance is due to 
its own mechanism of action. Antimicrobials are designed to directly inhibit the 
function and growth of the pathogen5. In short, once the pathogen develops 
mutatios or evolves, antimicrobial will lose their ability to surpress or inhibit the 
original targeted function of the pathogens. Mycobacterium tuberculosis is a 
prominent example of a pathogen that acquired multiple mutations which 
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eventually became known as “superbug” due to its propencity for developing 
resistance against multiple antimicrobial treatments7.  
 
Antimicrobial resistance has also emerged as one of the major causes of death 
worldwide8. A publication published by the Review on Antimicrobial Resistance in 
2014 concluded that antimicrobial resistance will be the number one cause of 
death in 20509. The study projected that antimicrobial resistance will contribute to 
more than 10 million deaths, which is much more than the amount of deaths 
causes by cancer9. In addition, globalization also contributes to the spread of 
antimicrobial-resistance pathogens9. Reflecting upon the urgency of antimicrobial 
resistance, there is a huge need to address the problem by discovering new 
alternative therapies against infectious diseases. 
 
Host-Oriented Therapies as a Solution 
In order to address the current problems of antimicrobial therapies, having a  
understanding of host protein and pathogen interactions is important, as it will 
help to unveil a way to discover and develop new therapies that directly target 
host proteins or “host oriented therapies”. Different than antimicrobial therapy, 
also known as “pathogen oriented therapies”, host oriented therapies aim to 
directly target host protein(s) that are exploited by the pathogen. This approach is 
very robust and lucrative, as it has the advantage of circumventing the 
development of drug resistance due to pathogen mutations.  
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Pathogens require the cooperation of host cell proteins to enter, replicate, and 
exert their toxicity/activity. Once pathogens bind with receptors on the outer cell 
membrane, the host cell will start the process of cell signalling and eventually 
internalize pathogens and proteins complexes via endocytosis or phagocytosis. 
Once it gets into the inner membrane, different proteins will help mediate the 
release of pathogens into the cytosol. Pathogens will then exert their pathogenic 
effects through different types of mechanisms which eventually lead to host cell 
death.  
 
Studies have shown that different types of pathogens may share similar 
pathogenic pathways in their expolitation of host cells10. Viruses such as 
Leishmania, Chlamydia, HIV, and SV40 share similar entry mechanisms while 
having different exit mechanisms.  Leishmania, Chlamydia, and HIV travel to the 
endosome before being tranlocated to the cytosol. Meanwhile SV40 will undergo 
retrogate transport through the Golgi to the Endoplasmic Reticulum (ER) before 
being translocated into cytosol where it eventually kills the host cell10. Similar to 
viruses, bacterial toxins such as Diphtheria, Anthrax, Botulinum, Cholera, Shiga, 
and Ricin toxins also share similar entry mechanism pathways. Diphtheria, 
Anthrax, and Botulinum toxins bind with receptors before being internalized, and 
travel into endosomes prior their release into cytosol; Cholera and Shiga toxins, 
as well as Ricin all undergo retrogate transport through the Golgi to the 
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Endoplasmic Reticulum (ER) before being translocated into the cytosol where 
they eventually kill the host cells10. 
 
Figure 3: Different pathogens may share similar pathways  of introducing 
their pathogenicity10.  
 
As it has been previously described, different pathogens may share similar 
pathways of introducing their pathogenicity into the host. In addition, there are 
multiple host proteins that mediate the entry and exit mechanisms of the 
pathogens (Table 1). Therefore, the hypothesis of host oriented therapies may 
offer additional benefits to be used as potential broad specturm therapies, as 
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Table 1: Different pathogens exploit similar host proteins to introduce their 
pathogenicity 
 
The benefits of host oriented therapies have been proven safe, as their use is 
well developed in fields other than infectious diseases. One of the prime 
examples of host oriented drugs are statins, drugs known for treating cholestorol. 
Statins direcly bind and alter the conformation of HMG-CoA reductase enzyme26. 
The alteration of HMG-CoA reductase enzyme will eventually inhbit the 
conversion process of HMG-CoA into mevalonic acid, a cholesterol precursor26. 
As a result, sterol regulatory element binding proteins (SREBPs) are induced and 
increase the experession of LDL receptor which help to reduce LDL circulation26. 
Based on this example, there is a strong hypothesis that host oriented drugs 




There are two main tools that are being utilized for research: drug libraries and 
multiple bacterial toxins. Our drug library was purchased from John Hopkins 
University, and is known as the John Hopkins Clinical Compound Library 
(JHCCL). The main purpose of utlizing this library was because it it is one of the 
most extensive drug libraries, that includes 1,581 small molecule drugs that have 
either been previously approved by the FDA, most of which are off-patent27. The 
safety and pharmacokinetic profiles of these drugs, as they were used in 
patients, is widely available, which creates opportunities for quick and low-cost 
drug development27. Multiple bacterial toxins such as anthrax, diphtheria, 
cholera, and P. aeruginosa exotoxin A were used, because the mechanisms 
underlying their pathogenicity are well understood.  
 
Research Approach and Strategy 
The research aim is to identify potential host oriented drugs, host protein targets, 
and broad spectrum applications of the drugs in infectious disease. Figure 4 
outlined two research designs and strategies for discovering potential host 
oriented inhibitors.  
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Figure 4: Research Design and Strategy to Identify Potential Host Oriented 
Drugs 
 
Both studies require an exentesive and deep understanding of common disease 
pathways, therefore multiple bacterial toxins are incorporated, as the pathway 
and the targets of each respective toxins are well understood and characterized. 
In Version 1, the drug library were screened utilizing anthrax and diphtheria toxin. 
The “multiplex hit” is defined as a drug that protects the cell from toxicity. Once 
the hit has been identified, multiple studies were designed to identify the specific 
host protein that is being targeted by the drug. The data that was derived from 
the experiments was then used to validate the broad specturm application of the 
drug using different types of toxins. A more in depth explanation of the Version 1 
study design can be found in Chapter 2 of this dissertation. 
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Version 2 was designed by considering the challenges of identifying specific host 
targets in Version 1.0. The study began by identifying overlapping host proteins 
in multiple disease pathways. Once the host protein was identified, both cellular 
and bio-chemical (multiplex) drug screens were performed to identify “hits”.  The 
broad spectrum application was then validated by testing the “hits” against 
multiple toxins that potentially utilize this host protein to introduce their 
pathogenicity. A deeper explanation of Version 2 study design can be found in 
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Figures): 
• Figure 1a and 1b 
• Figure 2a, 2b, and 2c 
• Figure 3a ,3b, 3d, and 3e 
• Figure 4a, 4b, 4c, and 4d 




Chapter 2 - Identification of agents effective against 
multiple toxins and viruses by host-oriented cell 
targeting 
Abstract  
A longstanding and still-increasing threat to the effective treatment of infectious 
diseases is resistance to antimicrobial countermeasures. Potentially, the 
targeting of host proteins and pathways essential for the detrimental effects of 
pathogens offers an approach that may discover broad-spectrum anti-pathogen 
countermeasures and circumvent the effects of pathogen mutations leading to 
resistance. Here we report implementation of a strategy for discovering broad-
spectrum host-oriented therapies against multiple pathogenic agents by multiplex 
screening of drugs for protection against the detrimental effects of multiple 
pathogens, identification of host cell pathways inhibited by the drug, and 
screening for effects of the agent on other pathogens exploiting the same 
pathway. We show that a clinically used antimalarial drug, Amodiaquine, 
discovered by this strategy, protects host cells against infection by multiple toxins 
and viruses by inhibiting host cathepsin B. Our results reveal the practicality of 
discovering broadly acting anti-pathogen countermeasures that target host 




Whereas medical treatments generally target specific cellular functions of 
patients to cure or mitigate the effects of diseases, the strategy underlying 
treatment of infectious disease treatment is to target the infecting pathogen 28. 
Inevitably, and not surprisingly, the targeting of pathogens has led to the 
emergence and spread among pathogens of mutational resistance to 
countermeasures. Such resistance, together with a desire to expand the utility of 
countermeasures by increasing their range of therapeutic efficacy, has in recent 
years sparked interest in agents aimed at host functions that pathogens exploit to 
enter or be released from host cells 28. Not infrequently, multiple pathogens or 
toxins that affect hosts by different mechanisms use the same host pathways 29, 
raising the prospect that multiplex strategies that concurrently or sequentially 
screen for host functions exploited by multiple pathogenic agents may lead to the 
discovery of broadly active and host-oriented infectious disease 
countermeasures. 
 
Here we report the discovery, using a cell-based multiplex approach to screen a 
library of FDA-approved drugs for the ability to interfere with disparately acting 
pathogens. We report here, that a compound used clinically as an antimalarial 
agent, inhibits both the detrimental effects of multiple bacterial toxins and the 
entry of Ebola and other viruses into host cells. We further show that the broad 
anti-pathogenic actions of Amodiaquine result from its ability to interfere with the 
functioning of the host protein, cathepsin B. 
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Results  
Screening of FDA approved drugs for inhibitors of toxin - induced cell 
death 
In a systematic effort to identify candidates for repurposing drugs as broad-
spectrum, host-oriented, anti-toxin countermeasures, we screened members of 
the Johns Hopkins Clinical Compound Library (JHCCL) 30 of 1,581 agents 
previously approved as drugs by the U.S. Food and Drug Administration for the 
ability to reduce lethality of RAW264.7 and C32 cells treated either with Bacillus 
anthracis lethal toxin or diphtheria toxin (Fig. 1a). These toxins were chosen 
because the mechanisms underlying their pathogenicity are well understood and 
are disparate to each other. 
 
Figure 1a: Schematic diagram of cellular screens to identify drugs that 
reduce cellular lethality induced by anthrax lethal toxin, LF and PA (LT) and 
diphtheria toxin (DT).   
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Between 50 and 70 percent of cells used for these assays normally undergo cell 
death, as determined by MTT assay, within 6 and 24 hours of exposure to 
anthrax lethal toxin and diphtheria toxin respectively, under the experimental 
conditions employed. A “hit” in our screen was defined as an event where cells 
exposed to a compound at a concentration of 16µM increased cell survival by at 
least 16 standard deviations (~1% hit rate) above the survival of control cells 
treated with either toxin, but is not cytotoxic to cells in the absence of toxins. 
Events defined as “multiplex hits" interfered with cell killing by both of the toxins 
(Fig. 1b). Five multiplex hits were identified and were tested further.  
 
Figure 1b: The distribution of inhibitors obtained in those screens, with a 
table showing the routes taken by toxins to enter into cellular cytoplasm 






Figure 1c: Schematic depiction of the host pathway that mediates the 
delivery of anthrax toxin into cytoplasm. Lethal factor (LF) and edema 
factor (EF) interact with a third B. anthracis-generated protein, protective 
antigen (PA). Three host cell proteins CMG2, TEM8, and ITGB1 can serve as 
receptors for the bipartite PA/LF and PA/EF toxins. Fifteen additional host 
proteins are known to assist PA binding and/or internalization. 
 
Anthrax toxin and diphtheria toxin enter the cytoplasm from acidified endosomes 
31. Whereas diphtheria toxin is an ADP ribosyltransferase, anthrax toxin is a 
protease that cleaves host MAPKK (Fig. 1c). To identify agents that inactivate 
host proteins exploited by toxins, we focused on hits that inhibit the 
mechanistically differently acting anthrax and diphtheria toxins. In order to 
elucidate host-targets inhibited by these drugs we used only anthrax toxin, as the 
host cellular pathway that delivers the anthrax toxin into the cytoplasm is one of 
the best understood pathways (32 and Fig. 1c). Anthrax lethal toxin is an exotoxin 
protein complex consisting of protective antigen (PA) and lethal factor (LF), which 
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act collectively to damage the host cell 11. PA is an 83 kDa cellular receptor-
binding protein (PA83), and the combination of PA with LF is cytotoxic 11. LF is a 
91 kDa zinc metalloprotease that cleaves the N-terminal substrate docking site of 
the mitogen-activated protein kinase kinases (MAP2K), preventing the passage 
of signals in the ERK1/2, p38, and c-Jun N-terminal kinase pathways 33. 
Intoxication of a cell begins when PA83 binds to host cellular receptors, capillary 
morphogenesis protein 2 (CMG2), tumor endothelial marker 8 (TEM8), or integrin 
beta 1 (ITGB1) 29,34,35. Once bound, host furin cleaves a 20 kDa fragment from 
the N-terminus of PA83, thus activating the 63 kDa protein, PA63 36. Following 
activation, PA63 forms a heptamer and binds LF 37. The toxin undergoes clathrin-
mediated endocytosis and a decrease in endosomal pH induces the formation of 
an endosomal membrane PA channel, by which LF translocates into the cytosol 
38 before PA pores are transported to lysosomes for rapid degradation 34,39,40. PA 
has been shown to induce the process of autophagy, whereby autophagosomes 
encapsulate endosomes and facilitate the delivery of LF into the cytoplasm 41. A 
lysosomal protein, cathepsin B, is necessary for the autophagic flux, whereby LF 
is delivered from the intralumenal vesicles of the autophagosome-encapsulated 
multivesicular late endosomes into the cytoplasm through a back fusion process 
40,42,43. 
We observed that out of five compounds that inhibited anthrax and diphtheria 
toxins, two compounds were structurally related 4-amino-quinolines, Chloroquine 
and Amodiaquine. Two anti-malarial drugs, Chloroquine (CQ) and Amodiaquine 
(AQ), were observed to completely protect host cells against anthrax toxin killing 
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in 6-hours toxin killing assay (Fig. 2a). However, our assay showed that unlike 
AQ, CQ only has a moderate ability to protect cells against LF-PA mediated 24-
hours killing (Fig. 2b). Interestingly, none of the other quinoline-containing 
antimalarial compounds, Cinchonine, Primaquine, and Quinidine, from JHCCL 
were active (Supplementary Fig. 1a-c).  
 
Figure 2a and 2b: Amodiaquine and JHCCL available structural analogs 
were tested for their ability to inhibit LF-PA-mediated cytotoxicity. 
RAW264.7 cells were seeded at 1x104 cells/well on 96-well plates and the 
following day were incubated with indicated doses of Amodiaquine or 
Chloroquine for 1 h, followed by either 6h (a) or 24h (b) intoxication with 
500 ng/mL PA + 500 ng/mL LF. Cell viability was determined by MTT assay 
(Materials and Methods) and is shown as the percentage of survivors 
relative to cells not treated with drugs. 
 
Amodiaquine and its metabolite are potent inhibitors of LF-PA induced 
death in vitro and in vivo 
After oral administration, AQ is rapidly absorbed and undergoes fast and 
extensive metabolisation by hepatocytes’ cytochrome p450 enzyme to the AQ 
metabolite, Desethyl-Amodiaquine (DEAQ), the main active metabolite of AQ 42. 
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We tested the ability of DEAQ to reduce anthrax toxin mediated cellular killing, 
and observed that just like AQ, DEAQ was able to reduce toxin-mediated 
cytotoxicity with an EC50 of 5 µM (Fig. 2c). Since AQ and its metabolite, DEAQ, 
protected host cells against anthrax toxin killing, we evaluated the efficacy of AQ 
as a therapeutic agent during anthrax toxin intoxication in Sprague-Dawley rats. 
Animals were injected intravenously with a lethal dose of anthrax toxin (LD100) 
and were intravenously co-injected with AQ at 1.5, 3.0, or 6.0 mg/kg. The AQ 
doses were selected based on the FDA approved AQ dose of 10 mg/kg 44. 
Animals that received a lethal dose of anthrax toxin without AQ all died within 90 
minutes post intoxication (Fig. 2d). While the administration of AQ at 1.5 mg/kg 
saved 40% of the rats, all of the animals in that group displayed classical signs of 
having undergone a toxin challenge, such as ataxia, lethargy, hyperpnea, and 
tachypnea. Rats that were challenged with anthrax toxin and treated with AQ at 
3.0 and 6.0 mg/kg all survived without displaying toxin-associated symptoms 
(Fig. 2d).  
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Figure 2c and 2d: AQ and DEAQ were tested for their ability to inhibit LF-
PA-mediated toxicity in (c) RAW264.7 cells and in (d) Sprague-Dawley rats. 
RAW264.7 cells were seeded at 1x104 cells/well on 96-well plates and the 
following day were incubated with indicated doses of AQ or DEAQ for 1 h, 
followed by 6h intoxication with 500 ng/mL PA + 500 ng/mL LF. Survival 
curves of groups of male Sprague-Dawley rats challenged intravenously 
with 12 µg LF and 40 µg PA along with varying amounts of AQ (1.5, 3.0, and 
6.0mg/kg). Control groups of rats either received toxin only or 6.0mg/kg of 
AQ only. 
 
Amodiaquine Inhibits Cytosolic Entry of LF 
In order to identify the step at which AQ inhibits LF-PA-mediated lethality, we 
assessed the processes that mediate the cellular entry of this toxin and toxin-
induced pyroptosis in the presence and in the absence of this drug. Caspase-1 
activation, which occurs late in LF-PA intoxication, was monitored using a 
fluorescent probe, FLICA. This probe specifically binds to active caspase-1. 
While we observed high levels of caspase-1 activity upon LF-PA treatment in the 
absence of AQ, active caspase-1 was not detected in AQ-treated cells that were 
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challenged with anthrax toxin (Fig. 3a). This result shows that AQ inhibits 
cytotoxicity upstream of caspase-1 activation. 
 
Figure 3a and 3b: (a) AQ inhibits LT-mediated caspase-1 activation. 
RAW264.7 cells were seeded and allowed to adhere overnight, and then 
incubated with 16 µM AQ or DMSO for 1 h before addition of 500 ng/mL PA 
+ LF for 2 h. FLICA was added for a further 1 h and then cells analyzed by 
fluorescence microscopy. (b) AQ inhibits LT-mediated cleavage of MEK-2. 
RAW264.7 cells were incubated with AQ or DMSO for 1 h before addition of 
vehicle control or 1 µg/mL PA + LF for up to 2 h. Cells were lysed and 
analyzed via immunoblotting with a MEK-2–specific antibody. Tubulin was 
used as a loading control.  
 
Activation of caspase-1 by LF is a late step in pyroptosis, and depends on LF 
catalytic activity 45. To determine whether AQ blocks proteolysis of cellular 
MAPKKs by LF, we assessed the cleavage of MEK2 by immunobloting. While 
MEK2 was cleaved in LF-PA treated RAW264.7 cells, treatment with AQ 
completely prevented this effect (Fig. 3b). These results show that AQ inhibits 
either cytotoxicity upstream of MAPKK cleavage or blocks LF directly. 
In order to test whether AQ inhibits the enzymatic activity of LF, we used a 
Fluorescence Resonance Energy Transfer (FRET) based assay, in which an 
MEK2 peptide containing a cleavage site for LF with a fluorogenic DABCYL 
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group at the N-terminus and FITC quenching group at the C-terminus was used 
as LF substrate for in vitro assays. After cleavage by LF, the fluorescence 
emitted by the DABCYL increased (Fig. 3c). We tested the ability of AQ to inhibit 
the proteolytic activity of LF at 100 µM using FRET. In the presence of a known 
small molecule inhibitor of LF, surfen hydrate 46, no emission at 523 nm was 
seen (Fig. 3c). In the absence of any chemical inhibitor, LF cleaved MAPKK 
peptide, and the fluorescence emission was observed (Fig. 3c). A similar 
emission at 523 nm was observed when LF was able to cleave MAPKK peptide 
in the presence of AQ, which shows that AQ does not block the proteolytic 
activity of LF at 100 µM.  
 
Figure 3c: FRET data showing fluorescence emission from three reactions, 
where 5.8 µg/ml LF cleaves fluorescently labeled MAPKK peptide without 
drugs, in the presence of a known LF inhibitor, 100 µM surfen hydrate, or in 
the presence of 100 µM AQ.  
  
AQ-treated cells were found to be less sensitive to treatment with PA + FP59 
(Fig. 3d and e). FP59 is a hybrid toxin, which contains the PA binding site of LF 
as well as a toxin domain derived from P. aeruginosa exotoxin A 47, that has 
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been widely used as an LF surrogate, and kills cells by a different mechanism 29. 
This result, along with the caspase-1 and MEK2 data, strongly suggest that AQ 
interferes with PA mediated toxin entry.  
 
Figure 3d and 3e: (d and e) AQ protects cells from PA + FP59. RAW264.7 
cells were preincubated with a titration of AQ for 1 h, followed by a 6h 
intoxication with 500 ng/mL PA + LF (d) or FP59 (e). Cell viability was 
measured via MTT. 
 
Amodiaquine binds to and inhibits host cathepsin B 
In order for LF to reach the cytosol, PA83 must bind to host cell receptors, be 
cleaved by furin into PA63, heptamerize into a pre-pore form, bind LF, and 
proceed to low-pH endosomes where PA-heptamers undergo an acid-dependent 
conformational change from pre-pore to pore 48. Host-cell binding of PA and its 
proteolytic cleavage were monitored by immunoblot in the presence and in the 
absence of AQ. We observed that AQ did not block binding of PA83 to cells or 
block proteolytic processing of PA to generate PA63 (Fig. 4a). The inability of AQ 
to block the activity of host furin cleavage of PA83 is consistent with our 
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observation that AQ equally reduces sensitivity of host cells to both PA83+LF 
and PA63+LF treatments (Supplementary Fig. 2). These results indicate that AQ 
blocks intoxication at a step downstream of PA binding and assembly on the 
host-cell surface.  
 
Figure 4a and 4b: a) AQ does not inhibit PA binding to RAW264.7 cells. 
Cells were incubated with AQ for 1 h at 4°C before addition of 1 µg/mL PA 
for an additional 1 h. Cells were lysed and analyzed by immunoblotting with 
a PA-specific antibody. (b) AQ neutralizes acidic vesicles. RAW264.7 cells 
were pre-treated with AQ or vehicle control for 1 h and then treated with 
500 ng/ml of PA for an additional hour at 37 °C before addition of 
Lysosensor Green DND-189 for a further 10 min. Cells were then visualized 
by fluorescence microscopy. 
 
CQ was previously shown to prevent endosomal acidification 49. Since AQ is 
structurally similar to CQ, we tested whether AQ neutralizes anthrax toxin 
induced endosomal acidification. We used Lysosensor Green DND-189 to probe 
acidic organelles in the cells. Lysosensor is a green fluorescent dye used for 
tracking acidic organelles in the cell. Neutralization of these compartments can 
be visualized as a loss in punctate-fluorescent structures. In the absence of AQ, 
PA-treated cells displayed Lysosensor fluorescence, and AQ markedly 
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decreased cell-associated Lysosensor fluorescence (Fig. 4b). These results 
predict that AQ may block the ability of PA to either access acidified endosomes 
or to form PA pores. It is known that the pore formation of PA, which results from 
exposure to acidic pH within endosomes, is resistant to dissociation by SDS and 
runs as an oligomer on SDS-PAGE 48. Surprisingly, treatment of cells with AQ 
resulted in higher, rather than lower, abundance of SDS-resistant PA-oligomers 
compared to cells treated with PA only (Fig. 4c).  
 
Figure 4c and 4d: (c) AQ results in increased abundance of PA pores.  Cells 
were pre-treated with AQ for 1h at 37°C and then were exposed to 1 µg/mL 
of PA at 37°C for 1h. Cells were lysed and analyzed by immunoblotting with 
a PA-specific antibody. (d). FRET assay showing the activity of purified 
human cathepsin B without drugs, or with addition of AQ, DEAQ, CQ, or 
DECQ at 4, 8, 16, 33, or 66 µM. 
 
A similar observation was reported by Ha et al 40, who showed that an inhibition 
of host lysosomal cathepsin B by an unrelated small molecule CA-074, resulted 
in (i) elevated accumulation of PA pores in late endosomes, (ii) the inability of LF 
to be released from the late endosomes into the cytoplasm, and (iii) results in 
reduction of cellular sensitivity to LF-PA. Upon formation of the SDS-resistant 
PA63 pore in acidic endosomes, PA pores are then transported to lysosomes for 
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rapid degradation 50. Ha et al showed that cathepsin B mediates the fusion of 
lysosomes with endosomes, and that this fusion is necessary for the release of 
LF from the endosomes into the cytoplasm 40. In order to gain further insight into 
the mechanism of AQ-mediated protection of cells against anthrax toxin killing, 
we tested whether AQ inhibits cathepsin B protease activity of purified human 
cathepsin B using a FRET assay. We observed that both AQ and DEAQ directly 
inhibit cathepsin B activity in a dose dependent manner without drug pre-
incubation, at drug concentrations used in cellular experiments (Fig. 4d). We 
tested whether AQ inhibits cathepsin B in RAW264.7 cells. We observed that 
cells pre-treated with AQ or with DEAQ for 1 hour lost cathepsin B enzymatic 
activity in a dose dependent manner (Supplementary Fig. 3a). In addition, we 
tested the ability to AQ to inhibit cathepsin B activity in a protein lysate from cells 
that were not exposed to drugs prior to the lysis and observed that AQ and 
DEAQ inhibited cathepsin B activity (Supplementary Fig. 3b). We determined that 
the addition of drugs to cathepsin B reactions did not change the pH (pH 5.8) of 
the reaction buffer. In all of the cathepsin B experiments we observed that CQ 
and its metabolite, Desethyl-Chloroquine (DECQ), were weaker inhibitors of 
cathepsin B activity (Figs. 4d and S3), which corresponds to the phenotypic data 
seen in Fig. 2.  
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Figure 4e and 4f: (e) 1H-NMR spectra of AQ in the presence of cathepsin B. 
The reference spectrum of AQ with its atoms labeled (top), and the STD 
spectrum (bottom) are shown. The data were collected using a 
protein:ligand ratio of 1:100 with on- and off-resonance saturation at 0.04 
ppm and 30 ppm, respectively.  (f) Chemical structure of AQ showing the 
atom-specific magnitude of the STD effects.  The STD effect was calculated 
according to the formula ASTD = (I0-Isat)/I0. All STD effects are expressed as a 
percentage relative to the H4 atom (100%). 
 
The interaction between AQ and cathepsin B was probed using saturation 
transfer difference NMR spectroscopy (STD). This technique is a powerful label-
free ligand-observed tool to study molecular interactions in solution 51,52. STD 
relies on the transfer of selective saturation (excitation) of the protein’s atoms to 
atoms located in the bound ligand. Two 1D 1H-NMR spectra are acquired—one 
in which the protein’s signals are selectively saturated (“on” resonance, Isat), and 
another in which no signals are saturated (“off” resonance, I0). Ligand binding is 
evident by the difference spectrum (I0-Isat), as only when binding occurs are the 
signals of the ligand affected. Figure 4e shows the 1H-NMR spectrum of 2 mM 
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AQ in the presence of 20 µM cathepsin B (ligand:protein molar ratio of 100:1), 
and its corresponding STD difference spectrum. The presence of AQ signals in 
the difference spectrum clearly indicates that it is binding to the enzyme. An 
inspection of the atom-specific effects provides insight into the mode of binding. 
Atoms in the quinoline backbone display the largest reduction in their intensities, 
suggesting that they are in close proximity to cathepsin B (Fig. 4f, atoms H4 and 
H5 exhibit STD effects of 100 and 97%, respectively). In contrast, the H9 and 
H10 methylene protons are modestly affected suggesting that in the complex 
they are located distal to hydrogen atoms in the protein. Interestingly, several 
atoms in the phenol ring display substantial STD effects suggesting that they are 
near the protein. This is consistent with the lower biological activities of AQ 
analogs that remove the phenol ring (Fig. 2 and Supplementary Fig. 1). The 
importance of the AQ quinoline ring revealed by STD is also compatible with the 
crystal structure of cathepsin B bound to nitroxoline, as this small molecule 
contains a quinoline moiety that interacts extensively with the enzyme 53.   
Amodiaquine inhibits pathogenicity of Ebola virus 
Upon observing that AQ protects cells from anthrax and diphtheria toxins, we 
hypothesized that AQ and DEAQ might also be able to inhibit the entry of Ebola 
virus. Ebola virus, among other viruses, requires low endosomal pH 54 as well as 
host cathepsin B function 55 for membrane fusion and infection of host cells. In 
fact, AQ and CQ have recently been reported to inhibit Ebola virus pathogenicity 
in cells 54,55. We re-tested AQ and CQ’s ability to inhibit Ebola virus abundance in 
infected HeLa cells by visualizing infected cells using immune-staining, and in 
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addition we tested the ability of their metabolites, DEAQ and DECQ, to inhibit 
Eboa virus propagation in cultured cells in vitro. To test AQ-mediated inhibition of 
viral propagation, we compared infection by Ebola virus (Kikwit) at MOI of 0.5 
with and without drugs for 48 hours. To detect infected cells, immuno-staining 
was completed with anti-Ebola-glycoprotein antibodies. AQ and DEAQ effectively 
inhibited propagation of Ebola virus in HeLa cells with EC50’s in the low µM 
range (Table 1): the EC50’s of AQ and DEAQ were 3.8 and 3.6 µM respectively. 
The EC50’s of CQ and DECQ in HeLa were 4.8 and 7.3 µM respectively. This 
data shows that DEAQ is more efficacious in inhibiting Ebola propagation 
compared to DECQ. Similar results were obtained by testing AQ, CQ, DEAQ, 
and DECQ for their ability to inhibit Ebola virus in primary human cell line, HFF-1 
(Supplementary Table 1). This result confirms that anti-viral effect of AQ is not 




EC50	µM	 SD	µM	 CC50	µM	 SI50	
EBOV	 AQ,	48h	 3.8	 0.38	 50	 13.2	
EBOV	 DEAQ,	48h	 3.6	 0.35	 50	 13.9	
EBOV	 CQ,	48h	 4.8	 0.57	 100	 20.7	
EBOV	 DECQ,	48h	 7.3	 0.55	 100	 13.8	
Table 1: The effect of AQ, CQ, and its metabolites, DEAQ and DECQ, on the 
pathogenicity of EBOV in HeLa cells. The ability of drugs to reduce the 




The life cycle of Ebola virus in cultured host cells is 20-24 hours. To more clearly 
evaluate effects of AQ and DEAQ on a single viral life cycle, we compared the 
inhibitory effects of these drugs after 24 and 48 hours of Ebola virus infection in 
cells. We observed that AQ and DEAQ are at least two times more potent after 
24h of infection (EC50’s 2µM), compared to 48h, during which time the 
secondary round of infection occurs and possibly slightly decreases the antiviral 




EC50	µM	 SD	µM	 CC50	µM	 SI50	
EBOV	 AQ,	24h	 2.38	 0.47	 >50	 >21	
EBOV	 AQ,	48h	 4.46	 0.44	 >50	 >11.2	
EBOV	 DEAQ,	24h	 2.15	 0.48	 >50	 >23.3	
EBOV	 DEAQ,	48h	 4.12	 0.36	 >50	 >12.1	
Table 2: The effect of time of AQ and its metabolite treatments on the 
pathogenicity of EBOV. The 50% effective (EC50, virus-inhibitory) 
concentrations and 50% cytotoxic (CC50, cell-inhibitory) concentrations 
were determined. CC50 divided by EC50 indicate the selectivity index (SI) 
value. 
 
Amodiaquine inhibits pathogenicity of other Category A, B, and C 
pathogenic agents that enter into host cytoplasm from acidified 
endosomes 
In addition to anthrax toxin 41, diphtheria toxin 56, and Ebola virus 55,57, other 
pathogenic agents SARS coronavirus 57, Venezuelan equine encephalitis virus 
(VEEV) 58, Rabies virus 59, Junin virus 60, Chikungunya virus 61, and Clostridium 
difficile toxin B 62 enter the cytoplasm from endosomes and all require the 
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acidification of endosomes. We demonstrated that all of those pathogenic agents 
are inhibited by AQ in their respective in vitro cellular assays (Table 3 and 
Supplementary Fig. 4a). We also tested the ability of DEAQ to inhibit 
pathogenicity of Junin and Chikungunya viruses, and observed that DEAQ 
inhibits those two viruses with EC50’s similar to those of AQ (Supplementary 
Table 2). 
Other pathogenic agents, including cholera toxin 63, Pseudomonas aeruginosa 
exotoxin A 64, Poliovirus 3 44, and Herpes simplex virus 1 65 are transported in a 
retrograde fashion to the endoplasmic reticulum (ER) and retrotranslocated into 
the cytoplasm by the host ER-associated degradation pathway 63,64. We 
observed that cytotoxicity mediated by those pathogens was not blocked by AQ 
(Table 3 and Supplementary Fig. 4b and c). In addition, the inability of AQ to 
inhibit cholera and Pseudomonas toxins, which are both ADP-
rybosyltransferases, suggests that AQ’s adverse effect on diphtheria toxin (Fig. 
1), which is also ADP-rybosyltransferase, occurs by inhibition of host cathepsin B 
only. 
Another group of pathogens enter the cytoplasm by ways that do not rely on the 
acidification of endosomes, and include Human Cytomegalovirus 66 and 
Respiratory syncytial virus 67. We determined that AQ did not reduce the 
pathogenicity of those viruses (Table 3). This data supports the conclusion that 




The discovery and development of novel drugs against biological threat agents 
such as Bacillus anthracis and Ebola virus, is an important concern worldwide. 
We have shown that AQ is a broad-spectrum drug that can be applied rapidly to 
cure biological emergencies caused by the several identified pathogens (Fig. 5). 
For example, the current Ebola crisis has already killed more than 10,000 people 
in 2014 and 2015. Repurposing of a compound with well-established safety and 
pharmacokinetic profiles — as well as proven high-volume GMP manufacturing 
— may be the only way that a therapy can be tested and deployed in time to 
protect the 21+ million people in the three hardest-hit West African countries.  
 
Figure 5: AQ reduces the activities of pathogens that enter into host 
cytoplasm from acidified endosomes by exploiting cellular cathepsin B. AQ 
does not inhibit the entry of pathogens that enter through a retrograde 
fashion to the endoplasmic reticulum (ER) and retrotranslocated into the 
cytoplasm by the host ER-associated degradation pathway or by pH-
independent entry into cytoplasm. 
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To help address this Ebola crisis, as we were preparing this manuscript, we 
communicated our discoveries to Médecins Sans Frontières (MSF, Doctors 
Without Borders), and encouraged them to explore whether the administration of 
AQ in West African countries hit by Ebola epidemic is associated with a reduced 
mortality due to Ebola infections. MSF conducted a study and observed that the 
administration of AQ provided a substantial protection against Ebola mortality 
and reduced the mortality risk by 31%, and in this study MSF acknowledged the 
authors of this study (https://www.youtube.com/watch?v=rTyoc4s1Mco). 
As seen in current Ebola epidemic, the human host can be co-exposed to 
numerous deadly pathogens and thus the infected individual will need to take 
numerous countermeasures (each with their own side-effects) to protect against 
multiple infectious organisms. Therefore, therapies capable of inhibiting multiple 
pathogens are needed. Broad-spectrum anti-pathogen drugs, capable of 
simultaneously inhibiting numerous unrelated pathogens, could be developed by 
targeting host proteins commonly exploited by those pathogens. In this work we 
show that AQ inhibits the host target rather than the pathogen, which makes AQ 
host-oriented broad-spectrum antimicrobial that is less likely to be circumvented 
by pathogen mutations that lead to microbial resistance to the countermeasure. 
AQ was discovered by Parke-Davis in the 1940s and was approved by the FDA 
as an anti-malarial in the late 1940s and early 1950s under the trade name 
Camoquine. AQ is currently on the WHO’s Model List of Essential Medicines. 
Today AQ is recommended as a frontline anti-malarial therapy in combination 
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with artemisinin. AQ belongs to the “quinoline antimalarials” (Reviewed in 68). AQ 
inhibits Plasmodium falciparum phosphoethanolamine methyltransferase, an 
enzyme found in malarial parasites but not in humans 69. Here we report that AQ 
also binds and blocks the function of host cathepsin B protein and thus entry of 
key pathogens into the cytoplasm. 
Since AQ has been used for the past 60 years, its safety and pharmacokinetic 
profiles are well known. For example, it has been determined that after oral 
administration in healthy subjects, AQ is quickly absorbed and biotransformed 
into its main active form, DEAQ, which in turn is slowly eliminated with a terminal 
half-life of 9-18 days.  The availability of PK values for AQ allows us to compare it 
to our in vitro data. The EC50 values for all of the tested pathogens inhibited by 
AQ or by DEAQ were at low µM range.  Importantly, the known Cmax values 
(maximal amounts of drug in the blood after oral administration) of DEAQ in 
humans are in low µM range 69-71, and are comparable to the DEAQ EC50 values 
found in vitro for tested pathogens. This means that it is possible to achieve anti-
pathogen effective AQ doses in blood by orally administered AQ.  
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Materials and Methods 
Chemicals and Reagents:  
All toxins were purchased from List Biological Laboratories. FP59 was a kind gift 
from S. Leppla (National Institute of Allergy and Infectious Diseases /National 
Institutes of Health, Bethesda, MD). An FDA-approved drug library comprising of 
1,581 drugs was purchased from Johns Hopkins, titled, Johns Hopkins Clinical 
Compound Library (JHCCL) version 1.0. The drugs arrived as 10mM stock 
solutions in sealed microtiter plates and were made using DMSO or water as 
solvents. Drugs were arrayed in 96-well plates and screened at a stock 
concentration of 3.3mM. Amodiaquine, Chloroquine, Cinchonine, Primaquine, 
and Quinidine were purchased from Sigma-Aldrich (St. Louis, MO, USA). All 
drugs were prepared at 10mM using DMSO as a solvent. Desethyl-amodiaquine 
and desethyl-chloroquine were purchased from Toronto Research Chemicals Inc. 
Anti–N-terminal MEK-2, anti-tubulin, and anti-PA antibodies were purchased from 
Santa Cruz Biotechnology. Purified human cathepsin B protein used for NMR 
experiments was purchased from ACROBiosystems. 
 
Cellular Drug Screens:  
RAW264.7-pGIPZ(-) 29 mouse macrophage cells were maintained in DMEM 
(Sigma-Aldrich) supplemented with 10% FBS (Bioexpress) and 100 µg/mL 
penicillin and 100 µg/mL streptomycin. RAW264.7-pGIPZ(-)  cells (10,000 per 
well) were seeded in 96-well plates (100 µl/well) 24 hours before the assay. 
During the drug library screen assay, 0.75µl of 3.3mM drugs were added to 150µl 
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of cell-containing media to achieve 16 µM of each compound per well. Cells were 
treated with compounds for 1 hour at 37 °C 5%CO2, and then challenged with 
anthrax toxins, such that the final toxins concentrations were 0.5 µg/ml. Cells 
were treated with toxin and drugs for 6 hours. As rodent cells are resistant to 
diphtheria toxin, C32 human melanoma cell line was used for diphtheria toxin 
screening, where cells were treated with 2 µg/ml for 24 hours. Determination of 
cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay was performed as described 72. Cell viability is shown as the 
percentage of surviving cells obtained relative to cells treated with DMSO  
(100%).  
 
FRET MAPKKide LF activity:  
For drug testing in 96-well plates, the reaction volume was 250 µl per well, 
containing 20 mM HEPES pH 7.2, 5 µM MAPKKide conjugated with DABCYL 
and FITC (List Biological Laboratories, Inc), and 100 µM of JHCCL compound. 
The reaction was initiated by adding LF to a final concentration of 5.8 µg/ml. 
Kinetic measurements were obtained at 37C every 40 sec for 40 min using a 
fluorescent plate reader. Excitation and emission wavelengths were 490 nm and 
523 nm, respectively, with a cutoff wavelength of 495nm. 
 
Toxins Treatments:  
Cells were seeded in a 96-well plate at a density of 10,000 cells/well 1 d before 
toxin treatment. Various concentrations of LF or FP59 combined with a fixed 
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concentration of PA (500 ng/mL) were added to the wells, and cells were 
incubated for 6 h at 37 °C. Cell viability was measured by MTT assay. In other 
toxin treatment experiments, cells were pre-treated with various concentrations of 
drugs, and then treated with constant concentrations of 8.3 µg/ml of C. difficile 
toxin B, 500 ng/ml of P. aeruginosa Exotoxin A, or 500 ng/ml of Cholera toxin for 
6 hours. RAW264.7 survival was measured by MTT assay. Each data point 
shown for MTT assays indicates the mean ± SD value obtained in triplicate 
assays done in a representative experiment. At least three such experiments 
were routinely carried out. 
 
MEK Cleavage Assay:  
RAW264.7 cells were pre-treated with 66.67 µM of AQ for 1 hour. Following the 
pre-treatment, the cells exposed to 1 µg/mL of PA and LF at 37°C for up to two 
hours in the presence of 16.67 µM of AQ. The cells were then washed with cold 
PBS for 5x and lysed with RIPA buffer containing a protease inhibitor mixture 
(Roche). Cell lysates were quantified using the BCA protein quantification kit 
(Pierce) and loaded onto 4-12% denaturing gels (Criterion XT Precast Gel, Bio-
Rad). After electrophoresis for several hours, the gel was transferred overnight to 
nitrocellulose membranes; membranes were probed with anti-MEK-2 or anti 
tubulin antibodies. Quantitative Western blot analyses of the bands were 
accomplished using the VersaDoc 1000 instrument (Bio-Rad) or Odyssey 
infrared imaging system (LI-COR Biosciences). 
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Biochemical Assay of PA Binding and Internalization: 
Cells were pre-treated with AQ as described above for 1h, either at 4°C for PA 
binding or at 37°C for PA internalization assays cells were exposed to 1 µg/mL of 
PA at 4°C for 1 h for binding assay or at 37°C for 1h for internalization assay. 
Cells were then washed with PBS solution three times and lysed in RIPA buffer 
containing a protease inhibitor mixture (Roche). Western blot analysis was 
performed using anti-PA antibody anti-tubulin monoclonal antibody (Sigma-
Aldrich). Chemiluminescence of bands and their relative intensities were 
revealed using a VersaDoc 1000 instrument (Bio-Rad). 
 
Caspase-1 Activity Assay:  
Cells were treated with AQ for 1 h before addition of 500 ng/ml LF-PA for an 
additional 2h. FAM FLICA™ Caspase 1 Assay Kit was obtained from 
ImmunoChemistry Technologies LLC. FLICA reagent was added for 1 h. FLICA 
fluorescence was visualized as follows: cells were washed three times in PBS, 
fixed in 4% (wt/vol) paraformaldehyde, and examined under a fluorescence 
microscope (DM5500 B; Leica).  
 
Staining Cells with Lysosensor Green DND-189:  
Cells were treated with AQ for 1 h before an addition of 500 ng/ml PA for an 
additional hour and then stained with Lysosensor Green DND-189 for 10 min at 
37°C. Cells were then washed and fluorescence was visualized as follows: cells 
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were fixed in 4% (wt/vol) paraformaldehyde, and examined under a fluorescence 
microscope (DM5500 B; Leica). 
 
Cathepsin B Activity Assay:  
Cathepsin B activity in total cell lysates was determined using an InnoZyme ™ 
cathepsin B activity assay kit (EMD Milipore) and performed according to the 
manufacturer’s instruction. Cathepsin B activity in cellular lysates was tested in 
the following way: RAW264.7 cells untreated with drugs were lysed, and equal 
amount of cathepsin B containing protein lysate was added to the substrate 
solution (EMD Milipore) with and without AQ, CQ, DEAQ, or DECQ at 
concentrations of 4, 8, 16, 33, or 66 µM. Cellular cathepsin B activity with and 
without drugs was tested by pre-treating cells with drugs for 1 hour, followed by 
lysing cells and testing cathepsin B activity with a fluorescently labeled substrate. 
The activity of 0.5 ng/µl of purified human cathepsin B was mixed with and 
without drugs without pre-incubation and detected with a fluorescently labeled 
substrate. Fluorescence intensity indicating cathepsin B activity was measured at 
an excitation wavelength of 370nm and emission wavelength of 450nm 
(Molecular Devices, Spectra Max 384 PLUS).  
 
Rat intoxication challenge:  
The rat studies were performed at Explora Biolabs, San Diego, CA following 
Institutional Animal Care and Use Committee (IACUC) approved protocols. Five 
Male Sprague-Dawley rats (226 to 250 g; Charles River) per group were used. 
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The toxin mixture was prepared for each group by mixing 12 µg of LF with 40 µg 
of PA or with 1.5, 3.0, or 6.0 mg/kg of Amodiaquine in a 500-µl volume per rat. 




All STD experiments were performed at 25⁰C using a Bruker Avance 500-MHz 
spectrometer equipped with a cryogenic probe. The pulse scheme employed 
excitation sculpting with gradients, and a 50 ms spin lock filter (T1ρ) to suppress 
signals originating from the water and protein signals, respectively 51. An 
irradiation power of 26 Hz was applied on-resonance at 0.04 ppm, and off-
resonance at 30 ppm, for a total saturation time of 4s. Spectra were collected in 
an interleaved manner to account for any temporal fluctuations. Separate control 
experiments were performed using samples of cathepsin B or Amodiaquine to 
confirm the selectivity of saturation. STD spectra were acquired with 4096 scans 
and 32k data points using a spectral width of 7002.8 Hz centered at 2352 Hz. All 
experiments were performed in deuterated tris buffer: 50 mM D11-Tris, 150 mM 
NaCl, pH 7.5 supplemented with 8% D2O. The sample used for STD 
measurements contained 20 mM and 2 mM cathepsin B and Amodiaquine, 
respectively. The STD NMR data were processed and analyzed using Topspin 
3.1 software (Bruker, Billerica Ma). STD effects were calculated according to the 
formula: ASTD = (I0-Isat)/I0, where Isat and I0 are the intensity of the Amodiaquine 




The procedures of all viral experiments are described in supplemental materials 
and methods. Specifically, infection of HeLa cells with Ebola was done using 
Ebola virus (Kikwit) MOI = 0.5 (calculated for 4,000 cells/well, assuming one 
complete round of replication of HeLa cells at 15±2 hrs after cell seeding). Cells 
were incubated with the virus for 24 or 48h. Infection was terminated by fixing 
samples in formalin solution, and immuno-staining was used to visualize infected 
cells. Cells were treated with anti-GP specific monoclonal antibody (6D8) (1 to 
1000 dilution) followed by anti-mouse IgG conjugated with Dylight488 (Thermo) 
(1 to 1000 dilution) in blocking buffer containing 3% BSA in PBS. Nuclei were 
stained with Draq5 (Biostatus) diluted in PBS buffer. Images were acquired on 
the Opera imaging instrument (Perkin Elmer) using 10x Air objective and four 






Figure 1: The effect of quinolone anti-malarials on sensitivities of cells 
treated with anthrax toxins. RAW264.7 cells were pretreated with indicated 
drugs at shown concentrations for 1 hour, and then treated with anthrax 



























Figure 2: Amodiaquine reduces cellular 
sensitivity to LF+PA83 and LF+PA63. RAW264.7 
cells were pretreated either with DMSO or with 
AQ for 1 hour, and then treated with 500ng/ml of 
LF in the presence of 1.5 µg/ml of either of PA83 



























Figure 3: The effect of Amodiaquine, Chloroquine, and 
their metabolites on the activity of host cathepsin B. 
FRET assay showing the activity of cathepsin B 
without drugs, or with addition of AQ, DEAQ, CQ, or 
DECQ at 4, 8, 16, 33, or 66 µM. RAW264.7 cells were 
treated with drugs for 1 hour prior to lysis and 
determination of cathepsin B activity (a), or untreated 
RAW264 cells were lysed, the lysate was treated with 





Figure 4: The effect of Amodiaquine on sensitivities of cells treated with 
bacterial toxins. RAW264.7 cells were pretreated with indicated AQ 
concentrations for 1 hour, and then treated with (a) 8.3 µg/ml of Clostridium 
difficile toxin B (CdTB), (b) 500 ng/ml of Pseudomonas aeruginosa Exotoxin 
A (PE), or (c) 500 ng/ml of Cholera toxin (CT) for 6 hours. RAW264.7  
 
Supplementary Tables 
Table 3: Amodiaquine, Chloroquine and theirmetabolites inhibit Ebola virus 
in HFF-1 cells. The effect of AQ, CQ, and its metabolites, DEAQ and DECQ, 
on the pathogenicity of EBOV in HFF-1 cells. The ability of drugs to reduce 
the abundance of Ebola virus (EBOV) in host cells was measured in cells 
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by fluorescent microscopy. The 50% effective (EC50, virus-inhibitory) 
concentrations and 50% cytotoxic (CC50, cell-inhibitory) concentrations 





EC50	µM	 SD	µM	 CC50	µM	 SI50	
EBOV	 AQ,	48h	 2.6	 0.19	 30	 11.4	
EBOV	 DEAQ,	48h	 2.1	 0.48	 30	 14.4	
EBOV	 CQ,	48h	 2.5	 0.88	 70	 28.0	
EBOV	 DECQ,	48h	 3.2	 0.62	 70	 22.1	
 
Table 4: Amodiaquine and its metabolite inhibits Chikungunya (CHIV) and 
Junin (JUNV) viruses in host cells. The effect of AQ and DEAQ on the 
pathogenicity of EBOV in HFF-1cells. The ability of drugs to reduce the 
abundance of viruses in host cells was measured in cells by fluorescent 
microscopy. The 50% effective (EC50, virus-inhibitory) concentrations and 
50% cytotoxic (CC50, cell-inhibitory) concentrations were determined. CC50 
divided by EC50 indicate the selectivity index (SI) value. 
Pathogen	 Drug	 EC50	µM	 SD	µM	 CC50	µM	 SI50	
CHIV	 AQ	 18.4	 0.56	 >50	 >2	
CHIV	 DEAQ	 17.3	 0.64	 >50	 >2.9	
JUNV	 AQ	 16.9	 1.92	 50	 3.0	
JUNV	 DEAQ	 13.8	 2.02	 40	 2.9	
 
Supplemental Materials and Methods: 
Screening Assays for Ebola virus (EBOV, Strain Kikwit). 
High Content Imaging virus infection assay 
Cell Culture and infection  
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HeLa cells (ATCC) were cultured for 3 days in T175 or T225 (Corning) flasks in 
culture media containing Minimum Essential Medium (MEM, Corning Cellgro) 
supplemented with 10% Fetal Bovine Serum (Hyclone), 1% L-Glutammine 
(Hyclone), 10 mM Hepes 7.0-7.6 (Sigma), 1% non-essential amino acids 
(Sigma). Cells were lifted using Trypsin-EDTA (Sigma, T3974) and 2,000 
cells/well were plated in 35µl of culture media into imaging 384 well assay plates 
(Aurora 384, IQ-EB, 384 IQ-EB/NB, 200mclear, #1052-11130) and incubated for 
about 20h before compound treatment. 
Compound treatment 
Treatment of the cells with test and control compounds was done 2 h prior 
infection. EC50 determination for test compound done with 2 fold step at least for 
10 doses starting from highest concentration of 100uM (with stock concentration 
of 10mM) using HP D-300 digital dispenser. Each dose dispensed directly from 
the concentrated stock with highest volume of 500nL. Concentration of DMSO in 
all wells was normalized to 1%. Cells were pre-treated with serially diluted 
compounds for 2 hours before infection.  Each dose were repeated 4 times on 
one plate (n=4).  
 
Infection 
Infection was done using Ebola virus (Kikwit) MOI = 0.5 (calculated for 4,000 
cells/well, assuming one complete round of replication of HeLa cells at 15±2 hrs 
after cell seeding) and 10ul of virus dilution was dispensed in each well except 
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column 2, representing “no infection control”. Cells were incubated with the virus 
for 24 or 48h. Infection was terminated by fixing samples in formalin solution. 
Immuno-staining assay 
Immune-staining was used to visualize infected cells. Cells were treated with 
anti-GP  specific monoclonal antibody (6D8) (1 to 1000 dilution) followed by anti-
mouse IgG conjugated with Dylight488 (Thermo) (1 to 1000 dilution) in blocking 
buffer containing 3% BSA in PBS. Nuclei were stained with Draq5 (Biostatus) 
diluted in PBS buffer. 
Image and Data analysis. 
Images were acquired on the Opera imaging instrument (Perkin Elmer) using 10x 
Air objective and four images/well were acquired. Signal from anti-virus staining 
was detected at 488nm emission wavelength and Nuclei at 640nm. 
Image analysis was performed using PE Acapella algorithms. Several well-based 
output parameters were measured including: Number of Objects (Nuclei) and 
Positive Virus Number of Objects (Ave of Intensity for virus specific signal). The 
% of Infected cells were calculated by Acapella directly as   
  
% !"#$%&$' !"##$  = !"#$%$&' !"#$% !"#$%& !" !"#$%&' (!)!"!"#$ !" !"#$%&' (!) ∗ 100 
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% infection rate was analyzed for each plate using Median of % Positive virus 




% Inhibition. Data normalization was done using GeneData Explorer software. 
Data was normalized on the plate based level converting the %Virus positive 
cells associated with each wells into % Activity = % of inhibition of infection (or % 
Inhibition or % INH). Control wells were indicated as follows:   
NC =Neutral control; Infection + DMSO (or minimal activity of inhibitor) 
BC = Blank control; No infection (or maximum inhibition of viral infection 
possible). Median of the values is used for all controls. 
 
   % !"ℎ!"!!"#$ = !"#$%& %!"#$% !"#$%$&' !" −  %!"#$% !"#$%$&'(!)!"#$%& %!"#$% !"#$%$&' !" −!"#$%& %!"#$% !"#$%$&'(!") ∗ 100% 
 
% Viability. Number of objects represented the amount of cells in each treated 
well and was also used as indication of the cyto-toxic or cyto-static effect. The 
numbers of objects were converted by GeneData Condeseo to % Viability for 
with a compound dose response. 
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   %!"#$"%"&' =  !"#$%& !"#$% !"#$!"!"#$%&'()"$ !"#$%& (!") ∗ 100% 
 
Dose response curve fitting analysis 
Analysis of dose response curve for % Inhibition and % Viability was used to 
determine EC50 and CC50, and was applying GeneData Condoseo software with 
Levenberg-Marquardt algorithm (LMA) for curve fitting strategy. The Curve-fitting 
applied validity criteria, such aschi2, SE logEC50, minimal number of valid data 
points, to indicate if curve fitting converging was successful and indicated in table 
with results. R2value quantifies goodness of fit. Fitting strategy was considered 
acceptable if it gave conversion with R2>0.8.  
Screening Assays for Venezuelan equine encephalitis virus (VEEV, Strain 
TC-83).  
Primary cytopathic effect (CPE) reduction assay. Four-concentration CPE 
inhibition assays are performed. Confluent or near-confluent cell culture 
monolayers in 96-well disposable microplates are prepared. Cells are maintained 
in MEM or DMEM supplemented with FBS as required for each cell line. For 
antiviral assays the same medium is used but with FBS reduced to 2% or less 
and supplemented with 50 µg/ml gentamicin. The test compound is prepared at 
four log10 final concentrations, usually 0.1, 1.0, 10, and 100 µg/ml or µM. The 
virus control and cell control wells are on every microplate. In parallel, a known 
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active drug is tested as a positive control drug using the same method as is 
applied for test compounds. The positive control is tested with each test run. The 
assay is set up by first removing growth media from the 96-well plates of cells. 
Then the test compound is applied in 0.1 ml volume to wells at 2X concentration. 
Virus, normally at <100 50% cell culture infectious doses (CCID50) in 0.1 ml 
volume, is placed in those wells designated for virus infection. Medium devoid of 
virus is placed in toxicity control wells and cell control wells. Virus control wells 
are treated similarly with virus. Plates are incubated at 37oC with 5% CO2 until 
maximum CPE is observed in virus control wells. The plates are then stained 
with 0.011% neutral red for approximately two hours at 37oC in a 5% CO2 
incubator. The neutral red medium is removed by complete aspiration, and the 
cells may be rinsed 1X with phosphate buffered solution (PBS) to remove 
residual dye. The PBS is completely removed and the incorporated neutral red is 
eluted with 50% Sorensen’s citrate buffer/50% ethanol (pH 4.2) for at least 30 
minutes. Neutral red dye penetrates into living cells, thus, the more intense the 
red color, the larger the number of viable cells present in the wells. The dye 
content in each well is quantified using a 96-well spectrophotometer at 540 nm 
wavelength. The dye content in each set of wells is converted to a percentage of 
dye present in untreated control wells using a Microsoft Excel computer-based 
spreadsheet. The 50% effective (EC50, virus-inhibitory) concentrations and 50% 
cytotoxic (CC50, cell-inhibitory) concentrations are then calculated by linear 
regression analysis. The quotient of CC50 divided by EC50 gives the selectivity 
index (SI) value. 
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Screening Assays for Herpes Simplex Virus 1 (HSV-1, Strain E-377) and 
Human Cytomegalovirus (CMV, Strain AD169).  
Human foreskin fibroblast (HFF) cells were prepared from human foreskin tissue. 
The tissue was incubated at 4°C for 4 h in Clinical Medium and then placed in 
phosphate buffered saline (PBS) to remove the red blood cells, and resuspended 
in trypsin/EDTA solution. The tissue suspension was incubated at 37°C and 
gently agitated to disperse the cells, which were collected by centrifugation. Cells 
were resuspended in 4 ml Clinical Medium and placed in a flask and incubated at 
37°C in a humidified CO2 incubator for 24 h. The media was then replaced with 
fresh Clinical Medium and the cell growth was monitored daily until a confluent 
monolayer has formed. The HFF cells were then expanded through serial 
passages in standard growth medium of MEM with Earl’s salts supplemented 
with 10% FBS and antibiotics. The cells were passaged routinely and used for 
assays at or below passage 10. 
Primary Cytopathic Effect (CPE) Reduction Assay.  Low passage (3-10) HFF 
cells were trypsinized, counted, and seeded into 96 well tissue culture plates in 
0.1 ml of MEM supplemented with 10% FBS. The cells were then incubated for 
24 h at 37oC. The media was then removed and 100 µl of MEM containing 2% 
FBS was added to all but the first row. In the first row, 125 µl of media containing 
the experimental drug was added in triplicate wells. Media alone was added to 
both cell and virus control wells. The drug in the first row of wells was then 
diluted serially 1:5 throughout the remaining. The plates were then incubated for 
60 min and 100 µl of a virus suspension was added to each well, excluding cell 
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control wells which received 100 µl of MEM. The plates were then incubated at 
37oC in a CO2 incubator for three days for HSV-1, or 14 d for CMV. After the 
incubation period, media was aspirated and the cells stained with crystal violet in 
formalin for 4h. The stain was then removed and the plates were rinsed until all 
excess stain was removed. The plates were allowed to dry for 24 h and the 
amount of CPE in each row determined using a BioTek Multiplate Autoreader. 
EC50 and CC50 values were determined by comparing drug treated and untreated 
cells using a computer program. 
Screening Assays for Rabies (Strain Flury). 
Confluent BHK-21 cells were prepared in T-150 flask. Cells were Trypsinized 
cells and made as cell suspensions.  50 µl of 5x105 cells/ml cell suspension 
(25,000 cells/well) were added into each well of the 96 well plates, except row H. 
2X concentration of antivirals were made (Isoprinosine and test drug(s)). 6 
concentration points are done. 100µl per well that will be tested for effective 
concentration (drug wells) and cytotoxic concentration (tox wells) were added. 
The rabies virus was diluted 1:1000. 50µl was added per well in the drug wells 
and virus control wells. This gave a final dilution of 1:4000. The final volume was 
200µl.  Additional media was added to fill up wells, ie: Tox wells were 100µl 2x 
drug, 50µl cells (5e5 cells/ml), and 50µl media. Plates were covered and 
incubated (37°C; 5 % CO2) for 5 days. After 5 days the Promega CellTiter-Glo 
Luminescent Cell Viability Assay was run using the Fluoroskan FL to scan for 
luminescence. 
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Screening Assays for Poliovirus 3  
Principal Viruses and Cells:   
Poliovirus: WM3, Cells:  LLC-MK2 clone 7.1  
CellTiter 96 (Cytopathic effect/Toxicity).  The primary screen is a cytopathic effect 
(CPE) reduction assay. Briefly, 96-well cultures of cells are infected with virus in 
the presence of test compounds and incubated for 4-7 days (depending on the 
specific virus/cells).  Each virus is pre-titered such that control wells exhibit 
approximately 95% loss of cell viability due to virus replication.  Therefore, 
antiviral effect, or cytoprotection, is observed when compounds prevent virus 
replication.  Each assay plate contains cell control wells (cells only), virus control 
wells (cells plus virus), compound toxicity control wells (cells plus compound 
only), compound colorimetric control wells (compound only, no cells or virus), as 
well as experimental wells (compound plus cells plus virus).  Cytoprotection and 
compound cytotoxicity are assessed by MTS (CellTiter®96 Reagent, Promega, 
Madison WI) dye reduction.  The % reduction in viral CPE (antiviral activity) and 
% cell viability (cytotoxicity) are determined and reported. 
 
Screening Assays for Respiratory syncytial virus and SARS CoV 
Principal Viruses and Cells:   
Respiratory syncytial virus (RSV):  Strain A-2 in Hep2 cells 
SARS CoV:  Strain Urbani in Vero76 cells 
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CellTiter-Glo (Cytopathic effect/Toxicity). The antiviral cytoprotection assays 
examine the effects of compounds at designated dose-response concentrations 
in specific cell types to test the efficacy of the compounds in preventing the virus-
induced cytopathic effect.  Ribavirin is included as a positive control drug for 
influenza and RSV, while calpain IV inhibitor is used for SARS antiviral assays. 
Subconfluent cultures of cells are plated into 96-well plates for the analysis of cell 
viability (cytotoxicity) and antiviral activity (CPE).  For the standard assay, drugs 
are added to the cells 24 hours later.  The CPE wells also received 100 tissue 
culture infectious doses (100 TCID50s) of titered virus. 72 hours later the cell 
viability will be determined. Measurement of viral-induced CPE is based on 
quantitation of ATP, an indicator of metabolically active cells.  The CPE assay 
employs a commercially available CellTiter-Glo® Luminescent Cell Viability Kit 
(Promega, Madison, WI), and is a reliable method for determining cytotoxicity 
and cell proliferation in culture.  The procedure involves adding the single 
reagent (CellTiter-Glo Reagent) directly to previously cultured, subconfluent cells 
in media.  This induces cell lysis and the production of a bioluminescent signal 
(half-life greater than 5 hours, depending on the cell type) that is proportional to 
the amount of ATP present (which is a biomarker for viability). 
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 Transition  
In Chapter 2, we utilized multiplex cellular drug screening to rapidly identify 
Amodiaquine as an anti-toxin and anti-viral treatment. In addition, we 
successfully identified cathepsin B as the protein target of Amodiaquine. The 
study also validates the broad-spectrum applications of Amodiaquie as a host-
oriented therapy. Although we were successfully showed the multiplex, we found 
a limitation in our approach: multiplex cellular drug screening requires additional 
target identification steps to discover the host protein target of a drug in the cell. 
In an effort to improve and streamline our technique, we merged drug screening 
and protein target identification into one process. Chapter 3 outlines our new 
approach of multiplex drug screening. We performed parallel biochemical and 
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William Leonardi performed the following experiments (presented on Figures): 
• Figure 2c, 2d 
• Figure 3b, 3c, and 3d 
• Figure 4d, 4e, 4f, 4g, and 4h 
• Figure 5a, 5b, 5c, 5d, 5e, and 5f 
• Figure 6c 
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Chapter 3 - Bithionol blocks pathogenicity of bacterial 
toxins, ricin, and Zika virus 
Abstract  
Diverse pathogenic agents often utilize overlapping host networks, and hub 
proteins within these networks represent attractive targets for broad-spectrum 
drugs. Using bacterial toxins, we describe a new approach for discovering broad-
spectrum therapies capable of inhibiting host proteins that mediate multiple 
pathogenic pathways. This approach can be widely used, as it combines genetic-
based target identification with cell survival-based and protein function-based 
multiplex drug screens, and concurrently discovers therapeutic compounds and 
their protein targets. Using B-lymphoblastoid cells derived from HapMap Project 
cohort of persons of African, European, and Asian ancestry we identified host 
caspases as hub proteins mediating lethality of multiple pathogenic agents. We 
discovered that an approved drug, Bithionol, inhibits host caspases and also 
reduces the detrimental effects of anthrax lethal toxin, diphtheria toxin, cholera 
toxin, Pseudomonas aeruginosa exotoxin A, Botulinum neurotoxin, ricin, and Zika 
virus. Our study reveals the practicality of identifying host proteins mediating 
multiple disease pathways and discovering broad-spectrum therapies that target 




In recent years, a better understanding of protein interaction networks has led to 
the identification of highly connected hub proteins and pathways that are 
commonly used by a number of different pathogens and in a range of diseases 73. 
These hubs represent promising targets for drug development.  
Most disease networks have the “small-world” property, where proteins are only a 
few interactions away from any other proteins 74. Therefore, inhibiting a given 
node can potentially affect the state of most nodes in its vicinity as well as the 
activity of the network itself. In this way, therapeutic inhibition of nodes and hubs 
within one disease network can affect other disease modules or pathways. Here 
we develop an approach to systematically identify broad-spectrum drugs that 
target proteins exploited by multiple human disease pathways (Fig. 1a). 
Frequently, multiple infectious pathogens or toxins that negatively affect hosts by 
different mechanisms exploit the same host pathways 75. This notion raises the 
prospect that multiplex approaches may lead to the discovery of broadly active 
and host-oriented infectious diseases countermeasures that target host functions 
exploited by multiple pathogenic agents. We use genetics and a new drug 
screening methodology to identify and characterize the previously approved drug 
Bithionol as an inhibitor of host caspases, which reduces pathogenicity of a wide 
range of pathogenic agents, including ricin, anthrax lethal toxin, Botulinum 
neurotoxin A, diphtheria toxin, Pseudomonas aeruginosa exotoxin A, cholera 
toxin, and Zika virus. 
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Figure 1a: Depiction of the concept where multiple pathogenic pathways 
overlap, and hub proteins (purple circles) mediate multiple disease 
pathways. This model proposes a drug screen design to look for 
compounds that simultaneously inhibit the function of the hub protein and 





Identification of host hub proteins exploited by multiple pathogenic toxins  
Cytotoxic bacterial and plant toxins have evolved to exploit host proteins and 
cellular pathways that mediate the entry of those toxins into host cells and to 
induce cell-death. Although toxins exploit unique host pathways, these pathways 
are interconnected. While anthrax, diphtheria, and Botulinum toxins reach the 
cytoplasm from acidified endosomes, cholera, Pseudomonas aeruginosa and ricin 
toxins are transported into the cytoplasm through the host ER-associated 
degradation pathway 63. These pathways interconnect at host “hub” proteins. 
Using one of those toxins, Pseudomonas aeruginosa exotoxin A (PE), we set out 
to identify such hub proteins by i) determining whether known genetic mutations in 
host proteins exploited by PE affect the sensitivity of host cells to this toxin, and ii) 
investigating whether these host proteins are also exploited by additional 
pathogenic agents. The protein hubs will be used as targets in drug screens, in 




Figure 1b: A depiction of the design of the current study. The known host 
pathways and host proteins exploited by pathogens (HPEP) are considered. 
HapMap cell lines are used to study the association between cellular 
sensitivity to Pseudomonas aeruginosa exotoxin A (PE) and genetic 
mutations in genes coding for proteins exploited by PE. Mutations in host 
caspases associate with altered sensitivity to PE, and these proteins are 
defines as disease network hubs, which will be used as targets for the 




The effect of caspase mutations on the sensitivity of human B-cells to 
P.aeruginosa exotoxin A 
It has previously been shown that PE exploits several host proteins for its binding 
to and entry into host cells 76 and initiates programmed cell death by inducing 
activities of host caspase-3, -6, and -7 21. We investigated whether known 
mutations in host proteins exploited by PE associate with altered cytotoxicity of 
the toxin in cells from tissues that are naturally attacked by this toxin. The 
availability of human B-cells, which are physiological targets of PE 77 through the 
HapMap Project 78 has provided us with an opportunity to test whether mutations 
in host proteins that constitute PE pathogenicity pathway affect the cellular 
sensitivity to this toxin. Our initial tests with cells from a few individuals revealed 
that their sensitivity to PE varies greatly. Remarkably, our further investigation of 
PE sensitivity of B-lymphoblastoid cells derived from 234 individuals in 
geographically and ethnically diverse human populations [87 Yoruba in Ibadan, 
Nigeria (YRI), 60 Utah residents with ancestry from northern and western Europe 
(CEU), 43 Japanese in Tokyo, Japan (JPT), and 44 Han Chinese in Beijing, China 
(CHB)] showed a prominent 200-fold difference in lethality to the toxin (Figs. 2a 
and b). The range in PE sensitivity, as measured by the dose required to kill 20% 
of the cells [log(1/LD20)], was similar in all four human cell populations (Fig. 2c). 
Analysis of toxin sensitivity in parent/children trios indicated that relative sensitivity 
to PE is a heritable trait (P-value <0.0001) (Fig. 2d).  
The widespread and unimodal distribution observed for log(1/LD20) (Fig. 2b) is 
likely a result of a polygenic inheritance model, consistent with evidence that 
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multiple host proteins mediate PE lethality 21,76. To learn whether genetic 
variations in the genes encoding for these proteins account for any of the variation 
in sensitivity of B-cells to PE seen in Fig. 2a, we tested the association of 
numerous previously reported mutations with PE sensitivity. Caspase-7 and -3 
mutations that were previously reported to associate with cancer and rheumatoid 
arthritis 79-83 demonstrated a significant association with PE sensitivity in the 
individual HapMap populations (CASP7, rs3814231, CEU, P = 0.01; CASP7, 
rs2227309, CEU, P = 0.02; CASP3, rs4647601, rs4647693, and rs1049216, East 
Asian populations CHB and JPT combined, P = 0.04 for each SNP) (Figs. 2e and 
S1). These results show that the activity of caspases affects host cell sensitivity to 
toxins, and that these proteins are potential therapeutic intervention points and 
targets for the following drug screens. In addition to PE, ricin and toxins of 
anthrax, diphtheria, Botulinum, and cholera induce programmed cellular death by 
activating host caspases 21,22,45,84-88 (Fig. 3a). Therefore, a drug screen against 
hub caspases is of great interest, as these proteins are exploited by multiple 




Figure 2: The effect of Bithionol on P. aeruginosa exotoxin A in human B-
lymphoblastoid cells. (a and b) Human lymphoblastoid cells sensitivity to P. 
aeruginosa exotoxin A (PE)-mediated toxicity. (a) 234 B-lymphocytes were 
treated with PE at concentrations shown. Cell viability was determined by 
Alamar Blue assay (Materials and Methods) and is shown as the percentage 
of survivors relative to cells treated with PE alone. The LD20 calculation for 
the most sensitive cell line is shown as an example. (b) LD20 values (ng/ml 
of PE) were calculated and expressed on an inverse log10 scale. For 
calculations, PE sensitivity is defined numerically as 1/LD20. (c) Population-
specific distribution of toxins sensitivities. CEU, YRI, JPT, and CHB denote 
European, Yoruba, Japanese, and Chinese Han, respectively. One CHB 
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outlier is excluded. For each population, the black bar represents the 
median log sensitivity; the box extends from the lower to the upper quartile 
and the whiskers extend to the most extreme data point. (d) Heritability of 
log sensitivity in Yoruba trios. Plot of the log toxin sensitivity of the children 
against the mean log toxin sensitivity of the parents. The heritability is 
estimated as the slope (0.74) of the regression of the children phenotype on 
the midparent phenotype. (e) In CEU caspase-7 SNP rs3814231 associates 
with log PE sensitivity. 
 
 
Figure 3a: The use of Clinical Compound Library (CCL) to screen for 
inhibitors of hubs of human disease networks. (a) Depiction of toxins as 
well as their pathways that induce caspase-mediated cell death. These 
toxins enter into host cytoplasm either from acidified endosomes or 
endoplasmic reticulum. Broad-spectrum anti-toxin drugs are screened to 
identify inhibitors of host caspases. 
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A multiplexed cellular screen for CCL drugs that inhibit cytotoxic activities 
of bacterial toxins exploiting unique but interconnected host pathways  
In an effort to identify existing drugs that might be repurposed as novel host-
oriented broad-spectrum therapies, we screened a Clinical Compound Library 
(CCL) 30 through multiplex-based drug screening (Fig. 3b). We searched for 
compounds capable of both i) reducing cytotoxicities of diphtheria toxin, cholera 
toxin, and PE, and ii) inhibiting proteolytic activities of host caspases-3, -6, and -7 
exploited by these toxins in biochemical assays (Figs. 3b-d). In principle, a 
combination of biochemical and cellular drug screens could provide drug hits that 
reduce toxins’ cytotoxicities by inhibiting host caspases, and thus, this approach 
could simultaneously provide drug candidates and their protein targets. 
We screened members of the CCL for the ability to reduce cell death of host 
RAW264.7 and C32 cells treated with PE, cholera toxin, or diphtheria toxin (Fig. 
3c). At the indicated doses, between 30 and 50 percent of RAW264.7 cells 
undergo cell death within 12 hours for Pseudomonas and cholera toxins. For C32 
cells, similar cell death was observed at 24 hours exposure to diphtheria toxin 
under the experimental conditions employed. A “hit” in our screen was defined as 
an event where cells exposed to a drug increased cell survival by at least 20 
standard deviations (~1% hit rate) above the survival of control cells treated with 
either toxin, and is not cytotoxic to cells in the absence of toxins. Events defined 
as “multiplex hits” interfered with cell killing by at least two toxins. The two 
multiplex hits that were identified as capable of reducing the cytotoxicities of all 
three toxins were Bithionol and Pyrogallol (Fig. 3b). 
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Figure 3b,c, d: Overall approach scheme: CCL is screened by a multiplex 
approach that incorporates biochemical FRET and cell survival assays 
looking for drugs capable of simultaneously inhibiting host caspases-3/6/7 
and reducing cytotoxicities of three bacterial toxins. The output of this 
approach is the discovery of broad-spectrum and host-oriented drug, 
Bithionol. c) Schematic diagram of cellular screens to identify drugs that 
reduce cellular lethality induced by diphtheria toxin, Pseudomonas 
aeruginosa exotoxin A, and cholera toxin. Numbers are the distribution of 
inhibitors obtained in all screens. d) Schematic diagram of parallel FRET 




A multiplex protein function-based screen for CCL drugs that inhibit 
proteolytic activities of host caspase-3, -6, and -7 
In parallel experiments, we screened the CCL for drugs that could inhibit the 
function of hub caspases-3, -6, and -7 (Fig. 3d) that mediate cytotoxicity caused 
by bacterial toxins used in our multiplex cellular drug screens (Fig. 3b). Caspase 
activities were induced in RAW264.7 cells by PE treatment. To screen and identify 
drugs that inhibit proteolytic activities of caspases we utilized a fluorescence-
based FRET assay. Optimized substrate peptides for caspase-3, -6, and -3/7 
proteolytic activities were used with a fluorogenic 7-amino-4-methylcoumarin 
group at the N-terminus and acetyl quenching group at the C-terminus. As a 
FRET substrate that is uniquely cleaved by caspase-7 hasn’t been identified, and 
since caspases-3 and -7 are close orthologues, we searched for caspase-7 
inhibitors that could block proteolysis of a caspase-3/7 – specific substrate and 
not caspase-3 – specific substrate. After cleavage by caspase the fluorescence of 
AMC at 460 nm increases, while inhibitors of caspases prevent it. Compounds 
that showed greater than 80% (~1% hit rate) inhibition were defined as hits and 
selected for re-validation and further studies. Events defined as “multiplex hits” 
interfered with proteolytic activities of at least two caspases. Bithionol was one of 
the three multiplex hits identified as capable of prominently reducing the 
proteolysis of all three caspase substrates (Figs. 3b and 4a-c). Since Bithionol 
was identified by both cellular and biochemical multiplex screens (Fig. 3b), we 
further investigated the efficacy of Bithionol and the breadth of its potential as a 
host-oriented anti-pathogenic agent. 
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Figure 4 a, b, c: Bithionol inhibits caspases. FRET data showing 
fluorescence emission from two reactions, where caspase-containing 
cellular lysate cleaves fluorescently labeled substrate peptide without 
drugs, or in the presence of 33 µM Bithionol. FRET substrates were specific 
for cleavage by caspase-3 (a), caspase-3/7 (b), and caspase-6 (c).  
 
Bithionol reduces the pathogenicity of a range of toxins by inhibiting host 
caspases 
To investigate the potency of Bithionol, we first performed drug titration curves in 
host RAW264.7 and C32 cells. We demonstrated that Bithionol was able to 
reduce diphtheria, cholera, and Pseudomonas toxins-mediated cytotoxicities with 
an EC50 of 10 µM (Figs. 4d-f). We tested the effect of different concentrations of 
Bithionol for the ability to inhibit the proteolytic cleavage of substrates specific for 
cellular caspases-3, 6, and 3/7. We observed a linear dose-dependent caspase-
inhibitory efficacy of Bithionol, with IC50 of 21, 13, and 11 µM for caspases-3, -6, 
and -3/7, respectively (Fig. 4g). These results are consistent with anti-toxins 
EC50’s of Bithionol in cellular tests (Fig. 4d-f). 
We also tested whether Bithionol reduces cellular sensitivity to PE in randomly 
selected PE-sensitive HapMap cells. We observed that the drug protected three 
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cell lines treated with amounts of PE sufficient to kill 80% of cells (Fig. 4h). These 
results confirm the anti-toxin potential of Bithionol in host cells. 
Humans have 10 well-characterized caspases that collectively form a pathway, 
often referred to as “the caspase cascade”, where caspases-3, -6, and -7 are the 
executioners of cell death and are activated by other caspases 89. We tested the 
ability of Bithionol to inhibit activities of ten purified recombinant human caspase 
proteins, and we demonstrated that in addition to caspases-3, -6, and -7, Bithionol 
inhibited activities of caspases-1 and -9, while having no inhibitory effects on other 
caspases (Fig. 4i). Together, these results demonstrate that Bithionol is a direct 
inhibitor of a select subset of caspases, and that it reduces cellular sensitivity to 
toxins by targeting at least host caspases. 
 
Figure 4 d, e, f: Bithionol was tested for its ability to inhibit cytotoxicities 
mediated by toxins of cholera, diphtheria, and Pseudomonas. RAW264.7 
cells were incubated with indicated doses of Bithionol for 1 hour, followed 
by 12 hours intoxication with Pseudomonas and cholera toxins. Diphtheria 
toxin was added to C32 cells for 24 hours. Cell viability was determined by 
MTT assay and is shown as the percentage of survivors relative to cells not 
treated with drugs.  
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Figure 4g: Different concentrations of Bithionol are tested for their ability to 
inhibit caspase activity in cellular lysate of cells. Cells were pre-treated with 
Pseudomonas aeruginosa exotoxin A to induce caspases. FRET was done 
using substrates cleaved by caspases-3, -6, and -3/7.  
 
 
Figure 4h: Bithionol inhibits cytotoxicity mediated by P. aeruginosa 
exotoxin A in sensitive human B-lymphocytes. B-cells were seeded at 1X104 
cells/well on 96-well plates and were incubated with indicated doses of 
Bithionol for 1 hour, and then challenged with the toxin for 6 hours. Cell 
viability was determined by Alamar Blue assay and is shown as the 
percentage of survivors relative to cells not treated with drugs.  
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Figure 4i: Bithionol inhibits caspases-1, -3, -6, -7, and -9. Bithionol was 
tested at 33 µM for its ability to inhibit FRET reactions of purified human 
caspases-1 through 10. Percent inhibition values are shown, and compared 
to activity of caspases untreated with Bithionol. Phenogram of ten human 
caspases, assembled by Multalin using Dayhoff alignment parameters, is 
used to demonstrate relative homology of caspases. 
 
Bithionol inhibits cytotoxic activity of anthrax toxins  
Anthrax toxins, the major virulence factors of the Bacillus anthracis bacterium, 
include an exotoxin protein complex consisting of a protective antigen (PA) and 
lethal factor (LF) that act collectively to damage host cells. PA binds to cellular 
receptors, while LF acts as a protease cleaving cytoplasmic MAPKKs 90. Three 
additional host proteases mediate entry and lethality of anthrax toxin: furin, 
cathepsin-B, and caspase-1 40,45,90. 
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To test the ability of Bithionol to neutralize cytotoxic activity of anthrax toxin, we 
examined its effect on cell viability in LF-PA - treated RAW264.7 cells. While 80% 
of cells used for these assays normally undergo cell death within 6 hours of 
exposure to anthrax toxin, Bithionol provided substantial protection against LF-PA 
- mediated cell killing at 33 µM (Fig. 5a).  
Caspase-1 activation, which occurs in LF-PA intoxication, was monitored using a 
FRET assay. While we observed an induction of caspase-1 activity upon LF-PA 
treatment in the absence of Bithionol, caspase-1 induction was not detected in 
Bithionol-treated cells challenged with anthrax toxin (Fig. 5b). This result confirms 
that Bithionol inhibits anthrax toxin cytotoxicity by at least inhibiting caspase-1 
activity. 
We investigated whether additional anthrax toxin pathway proteases are inhibited 
by Bithionol in live cells. By utilizing MAPKK immunobloting (Fig. 5c), a hybrid 
toxin FP59 47 that enters host cells by utilizing PA, but kills cells by LF-
independent mechanism (Figs. 5d and e), and cathepsin-B FRET assay (Fig. 5f), 
we demonstrated that Bithionol does not inhibit proteolytic activities of cellular LF, 
furin, and cathepsin-B. 
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Figure 5a: Bithionol was tested for its ability to inhibit anthrax toxin-
mediated cytotoxicity. RAW264.7 cells were incubated with indicated doses 
of Bithionol for 1 hour, followed by 6 hours intoxication with anthrax toxin 
PA-LF. Cell viability was determined by MTT assay and is shown as the 
percentage of survivors relative to cells not treated with drugs.  
 
 
Figure 5b: Bithionol inhibits LF-PA – induced activity of cellular caspase-1. 
RAW264.7 cells were treated with LF-PA for 1 hour, and then treated either 
with 33 µM Bithionol or DMSO for 1 hour prior to lysis and determination of 




Figure 5c: MAPKK2 immunobloting showing that Bithionol does not block 
proteolysis of cellular MAPKKs by anthrax LF toxin. While MAPKK2 was 
cleaved in LF-PA treated RAW264.7 cells, treatment with Bithionol did not 
affect this process. RAW264.7 cells were incubated with Bithionol or DMSO 
for 1 hour before addition of vehicle control or 1 µg/ml PA + LF for up to 60 
minutes. Cells were lysed and analyzed via immunoblotting with a 
MAPKK2–specific antibody. Tubulin was used as a loading control.  
 
  
Figure 5d and 5e: Bithionol reduces cell death induced by the hybrid toxin 
FP59, which has been widely used as an anthrax LF surrogate and contains 
the PA binding site of LF, as well as a toxin domain derived from PE. 
Bithionol-treated cells were found to be less sensitive to treatment with PA 
+ FP59. PA was either in the native 83 kDa form (d), or used as 63 kDa – 
lacking 20 kDa Furin cleavage domain (e). RAW264.7 cells were 
preincubated with a titration of Bithionol for 1 hour, followed by a 6 hours 
intoxication with 0.5 µg/ml 83 kDa PA + FP59 or Furin processed 63 kDa PA 




Figure 5f: Bithionol doesn’t inhibit cathepsin B protease activity in 
RAW264.7 cells. RAW264.7 cells were treated with 33 µM Bithionol of DMSO 
for 1 hour prior to lysis, and determination of cathepsin B activity was 




Bithionol inhibits ricin and Botulinum Neurotoxin A - induced death in vitro 
and in vivo 
Ricin is another toxin known to induce host caspases-3, -6, and -7 is ricin 22,88. It 
reaches the mammalian cytoplasm through the retrograde transport route from 
the plasma membrane to ER via endosomes and the Golgi apparatus (Fig. 3a). 
Once in the cytoplasm, ricin inhibits cellular protein synthesis by cleaving a 
glycosidic bond within the large rRNA of the 60S subunit of eukaryotic ribosomes 
63. We tested the ability of Bithionol to reduce ricin - mediated cellular killing and 
observed that the drug was able to reduce toxin-mediated cytotoxicity with an 
EC50 of 10 µM (Fig. 6a). 
Botulinum neurotoxin serotype A (BoNT/A) is a protease that translocates into the 
host cytoplasm from acidic endosomes, where it cleaves the synaptosome-
associated protein, SNAP-25, and inhibits neurotransmitter release among 
neurons, leading to muscular paralysis 91. BoNT/A has been reported to cause 
cellular caspases-3 and -7 - dependent apoptosis 84.  
After oral administration, Bithionol crosses the intestinal epithelium and is 
absorbed into the bloodstream in humans and many animals 92. We evaluated the 
efficacy of Bithionol as a therapeutic agent during BoNT/A intoxication in Swiss 
Webster mice. Animals were given a lethal oral dose of BoNT/A complex in the 
presence and absence of Bithionol. Ninety percent of animals that received a 
lethal dose of BoNT/A without Bithionol died within 3 days of intoxication (Fig. 6b). 
All mice that were challenged with BoNT/A and treated with Bithionol at 6.0 
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mg/kg, survived without displaying toxin-associated symptoms, such as wasp 
waist and paralysis (Fig. 6b). 
Since BoNT/A acts as a protease, we investigated whether Bithionol directly 
inhibits the proteolytic activity of BoNT/A by utilizing a FRET assay. An optimized 
SNAP-25 peptide with a fluorogenic FITC group at the N-terminus and DABCYL 
quenching group at the C-terminus was used as the substrate 93. After cleavage 
by BoNT/A the fluorescence of FITC at 523 nm increases. We determined that 
Bithionol did not affect the proteolysis rate of the fluorescent substrate (Fig. 6c). 
This result shows that Bithionol protects mice by inhibiting host targets, rather 
than by inhibiting the toxin itself. 
 
Figure 6a: Bithionol reduces ricin mediated cellular killing. Human K562 
cells were incubated with indicated doses of Bithionol for 2 hours, and then 
challenged with ricin for 24 hours. Cell viability was determined by FSC/SSC 
flow cytometry.  
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Figure 6b: Ten Swiss Webster CFW mice were treated with 6 mg/kg 
Bithionol in the presence or absence of botulinum neurotoxin serotype A 
complex (BoNT/A) by oral gavage. Animals were observed over 7 days. The 
Bithionol and BoNT/A survival curves are statistically different based on the 





Figure 6c: Bithionol does not inhibit proteolytic activity of BoNT/A. FRET 
data showing fluorescence emission from two reactions, where 5 nM 
BoNT/A light chain cleaves fluorescently labeled SNAP-25 substrate peptide 









Bithionol acts as a Zika virus Inhibitor 
In addition to pathogenic toxins, viruses are also known to propagate by activating 
host caspases and inducing programmed cell death 94. Similarly to toxins, Zika 
virus (ZIKV) has been reported to lead to cell-death by inducing host caspase-3 
and neuronal apoptosis during its propagation 95,96. Moreover, caspases have 
previously been reported to cleave various viral proteins, affect viral protein 
localization, promote viral genome replication and viral assembly, and have been 
reported to be necessary for viral replication and propagation 97,98. 
Upon observing that Bithionol protects cells from caspase-inducing toxins, we 
hypothesized that Bithionol might also be able to inhibit the pathogenicity of the 
Zika virus. The strains utilized in this study were chosen to gauge the ability of 
Bithionol to inhibit Zika virus strains found within both ZIKV lineages. Both strains 
utilized in this study had low passage histories and had intact glycosylation sites. 
Furthermore, both strains were geographically and genetically divergent. Puerto 
Rico Zika strain, PRVABC59, is closely related to virus strains circulating in the 
New World including those strains isolated in Brazil and Guatemala. The African 
ZIKV lineage is ancestral to the Asian lineage; as such DAK AR D 41525 was 
selected as it is a low passage strain that is mycoplasma free. We tested 
Bithionol’s ability to inhibit Senegal and Puerto Rico isolates of ZIKV in infected 
Vero E6 cells and human astrocytes. To detect infected cells, immuno-staining 
was performed using anti-Flavi-virus envelope protein antibodies. Bithionol 
inhibited the abundance of Puerto Rico ZIKV in Vero E6 cells with EC50 of 6.7 µM 
as well as Senegal ZIKV in Vero E6 and human astrocytes with EC50’s of 5.5 and 
 83 
6.3 µM respectively (Fig. 6d and Table S1). These data indicate that Bithionol is 
effective in inhibiting ZIKV in host cells.  
 
Figure 6d: The ability of Bithionol to inhibit Zika virus (ZIKV) in host Vero E6 
cells and astrocytes was measured by fluorescent microscopy. The virus-




In order to discover the inhibitors of pathway hubs that mediate the lethality of 
multiple bacterial toxins, we identified host caspases as hubs and focused the 
discovery process on therapies that are able to inhibit caspases and reduce 
toxins’ cytotoxicities. Collectively, utilization of both cellular- and biochemical-
based multiplex drug screens provided us with i) a drug hit (Bithionol), ii) a drug-
target (caspases), and iii) an assessment of breadth of spectra of the drug. This 
disease-network-based approach utilizing two diverse multiplex drug screenings, 
which we term “Disparate Dual Multiplexing”, could significantly shorten the time 
needed for drug-discovery followed by target-identification steps in a historically 
lengthy process. In the future, additional types of drug screens could be included 
in disparate multiplex-based drug screens, such as genetic-based, and 
immunology-based screens, thus expanding our approach to Disparate Triple, 
Disparate Quadruple (etc.) Multiplex drug screening.  
Bithionol was previously approved to treat helminthes, and although the exact 
target within these species is not known, it is believed that the drug inhibits 
oxidative phosphorylation of parasites 99. Our study has uncovered five additional 
Bithionol targets: caspases-1, -3, -6, -7, and -9, which by definition makes 
Bithionol a polypharmacolocial drug. Polypharmacological phenomena include a 
single drug acting on multiple targets of either a unique or multiple disease 
pathways. Just like in the current study, many of the polypharmacological 
approaches aim to discover the unknown off targets for existing drugs, and this 
approach is called “drug repurposing” 75,100. Therefore, this raises the possibility 
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that Bithionol targets additional non-caspase host proteins exploited by toxins. To 
our knowledge, no other drugs used in humans have been reported to inhibit 
caspases. In the future, Bithionol can be investigated for its efficacy to treat other 
non-infectious human diseases caused by detrimental activities of caspases, such 
as neurodegenerative diseases and inflammatory bowel disease. 
Bithionol was replaced by the more effective anti-helminthic, Praziquantel 99. 
Moreover, Bithionol was used as a bacteriostatic additive in cosmetic products, 
but was discontinued in 1967 due to photosensitizing effects 92. Presently, 
Bithionol is still used to treat helminthic cases in some Asian and European 
countries and is included as an active ingredient in Fonergine®, used to treat 
mouth and throat disorders in Argentina 101. The current drug discovery and 
development process can take many years for the successful introduction of a 
new drug into the market. Thus, the current de novo drug discovery and 
development paradigm is ineffective for dealing with rapidly emerging biological 
threat agents. Under such circumstances, drug repurposing may offer numerous 
advantages. Since Bithionol already has a well-established safety and 
pharmacokinetic profiles in patients and animals, as well as bulk manufacturing 
methods 92, the drug could rapidly be made available for a new indication if a 
biological emergency was to occur. Most notably, it has been shown that after oral 
administration of 50 mg/kg of Bithionol in humans, the drug reaches serum 
concentrations that range from 225 to 480 µM 92, which is on average 30 times 
higher than the EC50 achieved by our cellular tests (Figs. 4-6). This suggests that 
it is possible to achieve effective anti-toxin and anti-Zika Bithionol doses in blood 
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by oral administration. In addition, Bithionol was i) used to treat cerebral 
paragonimiasis 102 and is known to cross the brain-blood barrier 103; ii) reported to 
cross the placental barrier 104; and iii) was used to treat paragonimiasis in a 
population that included children and pregnant women 105. All of these 




Materials and Methods 
Chemicals and reagents: All bacterial toxins were purchased from List Biological 
Laboratories (Campbell, CA). FP59 was a gift from Stephen Leppla (NIAID). Ricin 
was purchased from Vector Laboratories. Clinical Compound Library (CCL) drug 
library was purchased from Johns Hopkins University Bloomberg School of Public 
Health. Bithionol was repurchased from Sigma-Aldrich. 
 
Cell culture and cell lines: RAW264.7 mouse macrophage and human C32 
melanoma cells (ATCC CRL-1585) were maintained in DMEM (Sigma-Aldrich). 
Human B-lymphocytes were grown in IMDM (Invitrogen). Human K562 chronic 
myelogenous leukemia cells (ATCC CCL-243) were grown in RPMI 1640 Medium 
(Invitrogen). Vero E6 (ATCC CRL-1586) were maintained in MEM (Corning). 
Primary human Astrocytes (NHA-Astrocytes-AGM, Lonza, #CC-2565) were 
cultured in Astrocyte Basal Medium (Clonetics ABM, Lonza) supplemented with 
AGM SingleQuot Kit Supplement and Growth factors (CC-4123). All media were 
supplemented with FBS, penicillin, and streptomycin. 
 
Human B-lymphocytes sensitivity to Pseudomonas toxin-mediated lethality: 
Human B lymphocytes were treated with serial dilutions of P. aeruginosa exotoxin 
A for 48 hours. The viability of B cells was determined by Alamar Blue (AbD 
Serotec, BioRad) fluorescence, as described by the manufacturer. Each data 
point shown in Fig. 2a represents the average and SD of results from three wells. 
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Cell viability is shown as the percentage of survivors obtained relative to cells in 
the absence of the toxin (100% survival). LD20 was calculated for each cell line. 
Statistical analysis and graphical presentation were performed using GraphPad 
Prism software. A P value <0.05 was considered statistically significant. 
Homozygous medians were compared by an unpaired t test. CHB and JPT, two 
East Asian populations, were pooled in order to obtain a more accurate estimate 
of effect size in the larger combined population. Because linear regression is 
sensitive to outliers, we removed one outlier in CHB, as the log sensitivity of this 
cell line couldn’t be determined within the toxin range tested. 
 
Cellular drug screens: RAW264.7 cells (10,000 per well) were seeded in 96-well 
plates 24 hours before the assay. Cells were treated with compounds for 1 hour, 
and then challenged with either 2 µg/ml PE or 4 µg/ml cholera toxin for 12 hours. 
As rodent cells are insensitive to diphtheria toxin, C32 cells were treated with 2 
µg/ml of diphtheria toxins for 24 hours. Determination of RAW264.7 and C32 
viability was performed by MTT assay. Cell viability is defined as the percentage 
of surviving cells obtained relative to cells treated with DMSO (100% survival).  
 
Caspases FRET drug tests: Caspases were induced in RAW264.7 by treating 
cells with 2 µg/ml of PE for 4 hours. Caspases were extracted and their activity 
was measured using Caspase Assay Kit (Sigma-Aldrich) with or without drugs. 
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The FRET reaction was performed in 96 well plates, and each reaction contained 
16 µM substrate peptides (Peptides International) conjugated with a 7-amino-4-
methylcoumarin group at the N-terminus and acetyl group at the C-terminus. The 
amino acid sequences of substrates were: DNLD for caspase-3, DQTD for 
caspases-3 and -7, and VEID for caspase-6. CCL compounds were tested at the 
final concentration of 33 µM, as pilot testing indicated that CCL screen at 16 µM 
would not yield a sufficient number of multiplex hits. Reactions were initiated by 
adding caspase – containing lysate to a final concentration of 6 µg/ml. Kinetic 
measurements were obtained at 37ºC every 5 minutes for 2 hours using a 
fluorescent plate reader. Excitation and emission wavelengths were 360 nm and 
460 nm, respectively, with a cutoff wavelength of 365 nm. Rates of reactions were 
quantified by the Microsoft Excel LINEST function. A BioVision kit was used to 
test Bithionol’s ability to inhibit FRET reactions of purified recombinant human 
caspases-1 through 10. One unit of caspase was used in a single FRET reaction. 
 
Toxins treatments and cell viability assays: Cells (10,000 per well) were seeded in 
96-well plates 24 hours before the assay. Cells were treated with Bithionol for 1 
hour. RAW264.7 cells were challenged with anthrax toxins that include LF or 
FP59 and PA83 or PA63 (for 6 hours), PE (for 12 hours), or cholera toxin (for 12 
hours) at 0.5, 2, and 4 µg/ml respectively. C32 cells were treated with 2 µg/ml of 
diphtheria toxin for 24 hours. Determination of cells viability was performed by 
MTT assay. B-lymphocytes cells were seeded in a 96-well plates at 10,000 
cells/well 1 hour before toxin treatment, treated with Bithionol for 1 hour, and then 
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challenged with 8 µg/ml PE for 6 hours. Determination of lymphocyte viability was 
determined by Alamar Blue (AbD Serotec, BioRad) fluorescence, as described by 
the manufacturer. Each data point shown for MTT and Alamar Blue assays 
indicates the mean ± SD value obtained in triplicate assays done in a 
representative experiment. At least three such experiments were carried out.  
 
MAPKK2 cleavage assay: N-terminal MAPKK2, anti-tubulin, and anti-PA 
antibodies were purchased from Santa Cruz Biotechnology. RAW264.7 cells were 
pre-treated with 33 µM of Bithionol for 1 hour. Following pre-treatment, the cells 
were exposed to 0.5 µg/ml of PA and LF at 37°C for up to three hours in the 
presence of 33 µM of Bithionol. The cells were then washed with cold PBS five 
times and lysed with RIPA buffer containing a protease inhibitor mixture (Santa 
Cruz Biotechnology, Inc.). Cell lysates were quantified using the BCA protein 
quantification kit (Pierce) and loaded onto 4–12% denaturing gels (Criterion XT 
Precast Gel, Bio-Rad). After electrophoresis for several hours, the gel was 
transferred overnight to nitrocellulose membranes; membranes were probed with 
anti-MAPKK2 or anti tubulin antibodies. Quantitative Western blot analyses of the 
bands were accomplished using the Odyssey infrared imaging system (LI-COR 
Biosciences). 
 
Cellular cathepsin B and caspase-1 activity assays: Cathepsin B and caspase-1 
activities in total cell lysates were determined using an InnoZyme cathepsin B 
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activity assay kit (EMD Milipore) and caspase activity assay kit (BioVision), 
performed according to the manufacturers’ instructions. Cellular cathepsin B or 
caspase-1 activities with and without Bithionol were tested by pre-treating cells 
with 33 µM of Bithionol for 1 hour, followed by lysing cells and testing protease 
activities with fluorescently labeled specific substrates. Caspase-1 activities were 
induced by 1 hour pretreatment of cells with 0.5 µg/ml of LF + PA, and was 
compared to cells un-induced by the toxin. Fluorescence intensities indicating 
cathepsin B or caspase-1 activities were measured (Molecular Devices, Spectra 
Max 384 PLUS).  
 
Ricin treatment and cell viability assay: K562 cells were seeded at a density of 
2x105 cells/well in 24-well plates. Cells were pre-treated with Bithionol for 2 
hours and 0.4 ng/ml ricin was added to the treated wells. Following the 24-hour 
ricin treatment, the percent of viable cells (within the live gate by FSC/SSC) was 
measured by flow cytometry using a BD Accuri C6 Flow Cytometer. Experiment 
was performed in duplicate for each condition. 
 
Mice intoxication studies: 10 Swiss Webster (CFW) mice (6 week old) were 
treated with 0.125 mg/mouse Bithionol in the presence or absence of BoNT/A 
complex (3 µg/mouse, Metabiologics, Madison WI) in phosphate gelatin buffer 
(0.028 M sodium phosphate pH 7.0, 0.2% gelatin) by oral gavage. Animals were 
observed over a period of 7 days. Methods were carried out in accordance with 
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approved guidelines. All experiments were performed in accordance with relevant 
guidelines and regulations. All animal experiments have been approved by the 
Western Regional Research Center IACUC. Euthanasia protocols follow 
recommendations established by the American Medical Veterinary Association 
Guideline for Euthanasia to minimize animal pain and suffering. 
 
BoNT/A light chain FRET assay: The reaction volume was 250 µl per well in 96 
wells plate, containing 50 mM HEPES pH 7.4 containing 0.05% TWEEN 20, 5 µM 
SNAPtide (BoNT/A substrate peptide) conjugated with DABCYL and FITC (List 
Biological Laboratories, Inc), and 33 µM of Bithionol. Reactions were initiated by 
adding BoNT/A light chain to a final concentration of 5 nM. Kinetic measurements 
were obtained at 37ºC every 1 min for 50 min using a fluorescent plate reader. 
Excitation and emission wavelengths were 490 nm and 523 nm, respectively, with 
a cutoff wavelength of 495 nm. At least three such FRET experiments were 
carried out. 
 
Zika virus high content imaging infections assay: We utilized strains from both 
ZIKV lineages (African and Asian) to assess the potential for Bithionol to inhibit 
viral abundance. ZIKV strain DAK AR D 41525 was originally isolated from a pool 
of Aedes africanus mosquitoes in Senegal in 1984 (passage history: AP61#1, 
C6/36#1, Vero 3) and strain PRVABC59 was originally isolated from human sera 
in Puerto Rico in 2015 (passage history: Vero 6). Cells were pre-treated with 
Bithionol for 2 hours prior to infection. Vero E6 cells were exposed to ZIKV at an 
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MOI of 0.5; astrocytes were infected with ZIKV at an MOI of 15. Infection was 
terminated after 48 hours by fixing samples in formalin solution. For visualization 
of Zika infection cells were treated for 1 hour with anti-Flavi-virus envelop protein 
monoclonal antibody 4G2, followed by anti-mouse IgG conjugated with Dylight488 
(Thermo). Cells were stained with Hoechst (Life Technologies) for nuclei staining 
and with Cell Mask Red (Life technologies) for cytoplasm staining. Nuclei were 
stained with Draq5 (Biostatus) diluted in PBS buffer. Images were acquired on the 
Opera imaging plate reader (Perkin Elmer) and analyzed using Harmony and 







Drug Cells Virus (strain) EC50, !M SD, !M 
     
Bithionol Vero E6 Zika (Puerto Rico) 6.66 1.15 
     
Bithionol Vero E6 Zika (Senegal) 5.52 0.29 
     
Bithionol Human Astrocytes Zika (Senegal) 6.28 0.22 







 Table S1: The effect of Bithionol on the pathogenicity of Zika Virus in cells. 
The ability of Bithionol to reduce the abundance of Zika virus in host cells 
(Vero E6 and human astrocytes) was measured by fluorescent microscopy. 







 Figure S1a, 1b, 1c, 1d: Caspase-7 and Caspase-3 SNPs associate 
with log sensitivity of B-lymphoblastoid cells to Pseudomonas 
aeruginosa exotoxin A in indicated populations. 
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Supplemental Material and Methods 
Zika virus High Content Imaging infections assay: Vero E6 cells were seeded in 
384 plates (Aurora #1052-11130) at 2,000 cells/well in 40 !l of culture media for 
Zika virus infection assay. Astrocytes were lifted after culturing for 4 days using 
trypsin/EDTA (Lonza, #CC-5012) neutralized after 5 min by Trypsin neutralizing 
solution (Lonza, #CC-5002). Cells suspension was diluted with cultured media 
and plated at 20,000 cells/well in 96 well (Greiner, #655090). After 24 hours of 
incubation at 37°C with 5% CO2 cells were treated with Bithionol to determine its 
antiviral activity. Ten serial dilutions of Bithionol in quadruplicate were added 
directly to the Vero E6 cell cultures using the HP D300 digital dispenser (Hewlett 
Packard, Palo Alto, CA) in 2-fold dilution increments starting at 100 µM at 2 hours 
prior to infection. Astrocytes were treated with 6 serial dilutions in 3-fold increment 
and starting at 50 µM. To generate Negative control column 3 in 384 well plate or 
row H in 96 well plates were treated with DMSO only (1%). The DMSO 
concentration in each well was normalized to 1% using an HP D-300 digital 
dispenser. 
The ZIKV isolates used in this study were strain DAK AR D 41525 which was 
originally isolated from a pool of Ae. africanus mosquitoes in Senegal in 1984 
(passage history: AP61#1, C6/36#1, Vero 3) and strain PRVABC59 which was 
originally isolated from human sera in Puerto Rico in 2015 (passage history: Vero 
6). Two hours after treatment with compounds Vero E6 cells were infected with 
Zika virus at MOI = 0.5 (calculated for 4,000 cells/well, assuming one complete 
round of replication of Vero E6 cells at 15 ± 2 hrs after cell seeding). Human 
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primary astrocytes were infected with Zika at MOI = 15 calculated for seeded 
density of astrocytes. Column 2 in 384 well plate and row A in 96 well plates were 
left uninfected for positive control of inhibition. Infection was terminated after 48 
hours by fixing samples in formalin solution. Antiviral assays were done using a 
high content imaging technique for 384 or 96 well plates to quantify virus antigen 
production as a measure of virus infection. After pre-incubation of the cells for 30 
min with blocking solution containing 1X PBS with 3% BSA (Sigma) supplements 
with 0.1% Triton X-100 (Sigma) the primary Anti-Flavi virus Group Antigen 
Antibody, clone D1-4G2 was diluted 1000-fold in blocking buffer (1X PBS with 3% 
BSA) and added to each well of the assay plate. The assay plates were incubated 
for 60 minutes at room temperature. The primary antibody was removed and the 
cells were washed 3 times with 1X PBS. The secondary detection antibody was 
an anti-mouse IgG conjugated with Dylight488 (#405310, Thermo Fisher 
Scientific, Waltham, MA) diluted 1,000-fold in blocking buffer and was added to 
each well in the assay plate. The assay plates were incubated for 60 minutes at 
room temperature. Nuclei were stained using Hoechst 33342 (H3570, Invitrogen), 
and the cytoplasm of cells was counter-stained with Cell Mask Deep Red (Cat 
#C10046, Thermo Fisher Scientific, Waltham, MA) diluted in 1X PBS. Cell images 
were acquired using Perkin Elmer Opera confocal plate reader (Perkin Elmer, 
Waltham, MA) using 10X Air objective to collect five images per each well. Virus-
specific antigen was quantified by measuring fluorescence emission at a 488 nm 
wavelength, the nuclei staining was quantified by measuring fluorescence 
emission at a 400 nm and cytoplasm staining with Cell Mask at 640 nm. Analysis 
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of acquired images was done using Acapella PE software. A “no virus” control 
(Column 2) and a “1% DMSO” control (Column 3) were included on each plate to 
determine the 0% and 100% virus infection, respectively. Hoechst 33342 signal 
was used to generate nuclei mask and define each cell in the image. Cell Mask 
dye was used to better-defined area within the borders of the cells. The viral-
antigen signal was compartmentalized within the cell mask. The intensity of signal 
in the 488nm channel collected from the control wells containing no virus infection 
was used to determine the threshold for low signal. Those cells that exhibited 
antigen signal higher than selected threshold were counted as positive for viral 
infection. Ratio of virus positive cells to total number of analyzed cells was used to 
determine percent of infection positive cells for each well on assay plate 
 
Two parameters, total the number of nuclei in each well and total percent of 
infected cells collected for each well on the plates were exported from PE 
Acapella into PE Columbus Image data storage system and GeneData Screener 
(Genedata Inc, Lexington, MA) software for further data management and 
analysis. 
Data normalization was done on the plate level to allow comparison of the results 
from different experimental tests. The percent of inhibition of viral infection (% 
Activity or % Inhibition) was used to reflect decrease in percent of virus positive 
cells. The median of the values from the neutral control (NC) wells containing cells 
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with viral infection and treated with DMSO were used as a minimal activity of 
inhibitor or 0% inhibition. The median of values from Blank control wells (BC) 
containing cells not infected with virus were used as a threshold for the low signal 
and values were converted into the maximum inhibition of viral infection or 100% 
inhibition. (S)- samples, values from the wells treated with compounds. 
 
The values of % of infection and % of viability for each well was used in GraphPad 
Prism for curve fitting analysis using 2-4 parameter logistic (AC50, MAX, MIN, 




Chapter 4 – Future Directions and Concluding Remarks 
The research has successfully unveiled the importance and significance of host 
oriented therapies to treat multiple infectious diseases. The research has 
successfuly developed multiplex drug screening method that resulted in the  
discovery of two host oriented drugs: Amodiaquine and Bithionol. These drugs 
have shown to have efficacy and potential used to treat multiple infectious 
diseases in animals and potentially in humans. 
 
Our research has shown that Amodiaquine targets cathepsin B, a protein that 
plays major role in the release of the pathogenic agents into the cytoplasm. 
Mulltiple bacterial toxins and viruses such as anthrax toxin, diphtheria toxin, 
ebola, and rabies are also known to exploit cathepsin B during the infection 
process. The finding has been validated by testing the efficacy of Amodiaquine in 
vitro and in vivo. The efficacy of Amodiaquine in human has also been further 
tested and validated in human during 2014 ebola virus crisis in Africa. The 
broader application of amodiaquine are currently being evaluated through 
collaborations. The potential clinical trial study in Indonesia is being explored to 
test the potential use of amodiaquine against anthrax infection in livestock 
(cattle).  
 
The research has also shown that Bithionol targets caspases, proteins that plays 
major role by regulating cellular death (apoptosis). Multiple bacterial toxins and 
viruses such as ricin, Botulinum neurotoxin A, and Zika are known to exploit 
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caspases to help regulate cellular death of its host. The finding has been 
validated by testing the efficacy of Bithionol in vitro. Further study are still being 
performed, particularly to show the safety and efficacy of the drug in vivo. In 
addition, the broader application of Bithionol is currently being explored through 
collaborations. One of the collaboration that is currently being explored is to test 
the safety and efficacy of Bithionol to treat colic (abdominal pain) in horses. 
  
There are still broad applications of both Amodiaquine and Bithionol that can be 
explored as they target host proteins that are exploited by diseases other than 
infectious diseases. Further safety and efficacy validations need to be assesed to 
bring these two drugs into human clinical trials. 
 
The development of multiplex drug screening has successfuly helped our 
research to discover two drugs. Further application of multiplex drug screening 
still can be optimized by expanding drug library and different type of assays. 
These methods and technologies will help serve as a platform for many years to 
come to discover a fast, safe, and effective therapies against multiple diseases 
such as emerging and re-emerging infectious diseases. In addition, future PhD 
students may also utilize the method to potentially discover new proteins that 
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